Pseudo-solid-phase protecting group, method for producing nucleoside or oligonucleotide protector, oligoamidite precursor using the same
A pseudo solid-phase protecting group with an oxalic acid structure addresses safety concerns and yield issues in oligonucleotide precursor synthesis by enabling selective deprotection with safe compounds, facilitating efficient mass production of high-purity oligonucleotides and RNA-type oligoamidites.
Patent Information
- Application Number
- JP2023085573
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-24
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2043-05-24
AI Technical Summary
Conventional methods for producing oligonucleotide precursors using pseudo solid-phase protecting groups require the use of harmful or dangerous reagents like heavy metals, hydrogen gas, and lithium borohydride, posing safety hazards and yield issues, especially in the synthesis of RNA-type oligoamidites.
A pseudo solid-phase protecting group with an oxalic acid structure is developed, allowing selective deprotection using easy-to-handle compounds such as nucleophiles and bases or aliphatic amino alcohols, eliminating the need for hazardous materials and improving yield.
The new protecting group enables safe and efficient production of oligonucleotide precursors with high purity, suitable for mass production without the use of toxic substances, and can be applied to both DNA and RNA synthesis.
Smart Images

Figure 2024168691000001 
Figure 2024168691000002 
Figure 2024168691000003
Abstract
Description
[Technical field]
[0001] The present disclosure relates to a pseudo solid-phase protecting group, a protected nucleoside or oligonucleotide using the same, and a method for producing an oligoamidite precursor. [Background technology]
[0002] In general, the most widely used method for producing oligonucleotides is solid-phase synthesis using the phosphoramidite method with an automatic synthesizer. In recent years, with the increase in the development of nucleic acid medicines, there is an increasing demand for a method for mass-producing oligonucleotides, which are active pharmaceutical ingredients. However, since the manufacturing scale of solid-phase synthesis is limited to a few kilograms per run, liquid-phase synthesis is being developed as a method that allows for larger-scale production.
[0003] As a liquid phase synthesis method, a method for producing a protected oligonucleotide using a pseudo solid-phase protecting group has been proposed to solve the conventional problem of the complicated purification operation (e.g., Patent Documents 1 to 3). In recent years, a block synthesis method has been developed in which a previously prepared oligoamidite of dimer (2mer) or more is used for condensation in order to reduce by-products with chain lengths of N-1 and N+1 relative to the target oligonucleotide (e.g., Prior Document 4).
[0004] Here, in order to synthesize an oligoamidite precursor in which the nucleic acid base or phosphate group, which is the precursor of the oligoamidite, is protected, a selective deprotection step for removing the pseudo solid-phase protecting group is required (e.g., Non-Patent Document 1 and Patent Document 5). [Prior art documents] [Patent documents]
[0005] [Patent Document 1] JP 2010-275254 A [Patent Document 2] International Publication No. 2012 / 157723 [Patent Document 3] International Publication No. 2017 / 086397 [Patent Document 4] International Publication No. 2020 / 227618 [Patent Document 5] JP 2020-011932 A [Non-patent literature]
[0006] [Non-Patent Document 1] Y. Matsuno, et al., Org. Lett., 2016, 18, 800-803 Summary of the Invention [Problem to be solved by the invention]
[0007] However, the liquid phase synthesis methods described in Patent Documents 1 to 3 do not mention the synthesis of oligoamidite precursors (selective deprotection of pseudo solid-phase protecting groups).
[0008] In the block synthesis method of protected oligonucleotides using oligoamidites of 2 mer or more described in Patent Document 4, the building block on the 3' end side is synthesized using a pseudo solid-phase protecting group, whereas the building block (oligoamidite) on the 5' end side is synthesized using a tert-butyldimethylsilyl group (TBDMS group) instead of a pseudo solid-phase protecting group, and in order to obtain an oligoamidite precursor in high yield by selective deprotection, an excessive amount of dangerous hydrofluoric acid must be used. In addition, the TBDMS group is generally used as a protecting group for the 2'-position hydroxyl group during RNA synthesis, but in that case, it is difficult to selectively deprotect the TBDMS group that protects the 3'-position hydroxyl group, so it is considered that this method cannot be applied to the synthesis of RNA-type oligoamidites in which the 2'-position hydroxyl group is protected by a TBDMS group.
[0009] In the process described in Non-Patent Document 1, the pseudo-solid-phase protecting group is removed by catalytic reduction using a Pd catalyst, but toxic heavy metals and dangerous hydrogen gas must be used. In addition, this process takes a long time of about 20 to 40 hours. In the process described in Patent Document 5, the pseudo-solid-phase protecting group is selectively deprotected using lithium borohydride, but lithium borohydride is inactivated by moisture in the air, so it must be handled with care, and it reacts with water to generate hydrogen gas, which may lead to accidents such as fires and bubbling and overflow. In addition, in the synthesis of RNA having a substituent at the 2' position, such as fluorine, a methoxy group, or a hydroxy group protected by a TBDMS group, the selective deprotection yield is 53 to 67%, and there is a problem with the yield.
[0010] As described above, in the case of conventional pseudo-solid-phase protecting groups, the selective deprotection step of the pseudo-solid-phase protecting group required for synthesizing oligoamidite precursors in which the nucleic acid bases or phosphate groups that serve as precursors of the oligoamidites are protected requires the use of harmful or dangerous reagents such as heavy metals, hydrogen gas, and lithium borohydride, which poses handling issues for mass production, and improvements are required.
[0011] The present disclosure has been made in consideration of the above points, and an object of the present disclosure is to provide a pseudo solid-phase protecting group that is used in the production of oligonucleotides or oligoamidites and can be selectively deprotected using an easily handled compound, and a method for producing a protected nucleoside or protected oligonucleotide, or an oligoamidite precursor using the same. [Means for solving the problem]
[0012] As a technique for producing oligonucleotides, which are active ingredients of nucleic acid drugs, it is believed that a combination of two techniques, namely, a liquid phase synthesis method using pseudo solid-phase protecting groups for mass production and a block synthesis method for reducing by-products, will enable mass production of oligonucleotides with higher purity, but in order to achieve this, it is necessary to establish a mass production method for oligoamidite precursors. Therefore, the present inventors have conducted research into pseudo solid-phase protecting groups that can be selectively removed without damaging the protecting groups of the nucleic acid bases and phosphate groups of the protected oligonucleotides for the purpose of mass production of oligoamidite precursors, and as a result, have found pseudo solid-phase protecting groups that can be selectively removed using a combination of an easy-to-handle nucleophile and a base or a specific aliphatic amino alcohol.
[0013] The present disclosure is specifically as follows. The pseudo solid-phase protecting group of the present disclosure is a pseudo solid-phase protecting group used in the production of an oligonucleotide or an oligoamidite, and has the general formula (1): MO-(O=)CC(=O)-WXYZ (1) (In general formula (1), -OM represents a linking group that bonds to the 3'-position hydroxyl group of a nucleoside or oligonucleotide; M represents a hydrogen atom (H) or an alkali metal atom; W represents an oxygen atom (O), a sulfur atom (S) or NR (N represents a nitrogen atom, and R represents H or an alkyl group having 1 to 6 carbon atoms); X represents a single bond, an alkylene group having 1 to 12 carbon atoms (which may have an ether bond (-O-)), an arylene group (which may be substituted with an alkylene group having 1 to 3 carbon atoms) or a divalent heterocyclic group; Y represents a single bond, an ether bond, -OCO-, -NRCO- (R is the same as above), -CO- or -SCO-; and Z represents an alkoxyphenyl group or an alkoxyalkyl group having an alkoxy group having 10 to 30 carbon atoms.) and has an oxalic acid structure at the molecular end that binds to the 3' hydroxyl group of a nucleoside or oligonucleotide.
[0014] The protected nucleoside or oligonucleotide of the present disclosure is a protected nucleoside or oligonucleotide in which the 3'-position hydroxyl group is protected by binding with a pseudo solid-phase protecting group, and the pseudo solid-phase protecting group is the above-mentioned pseudo solid-phase protecting group.
[0015] The method for producing an oligoamidite precursor of the present disclosure is a method for producing an oligoamidite precursor in which the pseudo solid-phase protecting group is selectively deprotected from the protected oligonucleotide, and includes a selective deprotection step of selectively removing the pseudo solid-phase protecting group from the protected oligonucleotide by mixing the protected oligonucleotide with a nucleophile and a base. The nucleophile may include at least one selected from the group consisting of 2-cyanoethanol, 2-bromoethanol, 2,2,2-trifluoroethanol, methanol, ethylene glycol, 1,10-decanedithiol, 2-anilinoethanol, 2-aminobenzyl alcohol, and 2-aminophenol. The base may include at least one selected from the group consisting of triethylamine, N-methylmorpholine, N-methylimidazole, 4-dimethylaminopyridine, 4-pyrrolidinopyridine, pyridine, and dipotassium hydrogen phosphate.
[0016] The method for producing an oligoamidite precursor according to the present disclosure is a method for producing an oligoamidite precursor in which the pseudo solid-phase protecting group is selectively deprotected from the protected oligonucleotide, and includes a selective deprotection step of selectively removing the pseudo solid-phase protecting group from the protected oligonucleotide by mixing the protected oligonucleotide with an aliphatic amino alcohol. The aliphatic amino alcohol may include at least one selected from the group consisting of 2-(methylamino)ethanol, 2-[(hydroxymethyl)amino]ethanol, and diethanolamine. Effect of the Invention
[0017] As described above, according to the present disclosure, it is possible to provide a pseudo solid-phase protecting group that is used in the production of an oligonucleotide or an oligoamidite and can be selectively deprotected using an easily handled compound, and a method for producing a protected nucleoside or protected oligonucleotide, or an oligoamidite precursor using the same. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0018] The present embodiment will be described in detail below. The following description of the preferred embodiment is merely exemplary in nature and is not intended to limit the present invention, its application, or its uses.
[0019] <Pseudo solid phase protecting group> The pseudo solid-phase protecting group according to this embodiment is used in the production of oligonucleotides or oligoamidites in the same manner as conventional pseudo solid-phase protecting groups. The pseudo solid-phase protecting group is a protecting group that is bonded to the 3'-hydroxyl group of a nucleoside or oligonucleotide to protect the 3'-hydroxyl group.
[0020] The pseudo solid-phase protecting group according to this embodiment has the general formula (1): [C1] MO-(O=)CC(=O)-WXYZ (1) (hereinafter also referred to as "pseudo solid-phase protecting group (1)"). The pseudo solid-phase protecting group (1) has an oxalic acid structure "MO-(O=)CC(=O)-W" at the molecular end that binds to the 3'-hydroxyl group of a nucleoside or oligonucleotide. The pseudo solid-phase protecting group (1) has a structure different from conventional pseudo solid-phase protecting groups in that it has an oxalic acid structure at the molecular end on the side of the binding site with the 3'-hydroxyl group. The combination of the pseudo solid-phase protecting group (1) having an oxalic acid structure at the molecular end with a specific compound (hereinafter also referred to as "deprotecting agent") can achieve the desired effect of selectively deprotecting the pseudo solid-phase protecting group (1). Note that the conventional pseudo solid-phase protecting group is not deprotected under the same conditions (combined with a deprotecting agent).
[0021] In addition, the pseudo solid-phase protecting group (1) is deprotected under all general deprotection conditions for oligonucleotide synthesis. Furthermore, the pseudo solid-phase protecting group (1) is deprotected more quickly than conventional pseudo solid-phase protecting groups under all the deprotection conditions. For these reasons, the pseudo solid-phase protecting group (1) can be suitably used in oligonucleotide synthesis.
[0022] In general formula (1), "-OM" constituting one end of the oxalic acid structure represents a linking group that binds to the 3'-hydroxyl group of a nucleoside or oligonucleotide.
[0023] "M" represents a hydrogen atom (H) or an alkali metal atom. The type of alkali metal is not particularly limited, and examples thereof include lithium, sodium, potassium, rubidium, cesium, and francium. Potassium is preferable.
[0024] In the general formula (1), "W" constituting the other end of the oxalic acid structure represents an oxygen atom (O), a sulfur atom (S) or NR. "N" represents a nitrogen atom. "R" represents H or an alkyl group having 1 to 6 carbon atoms (hereinafter the same). Of "W", "O" is preferred.
[0025] Examples of the alkyl group having 1 to 6 carbon atoms include linear or branched alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, pentyl, and hexyl. Among the alkyl groups having 1 to 6 carbon atoms, linear alkyl groups having 1 to 6 carbon atoms are preferred, and methyl groups are more preferred. In addition, -WX- (W represents NR) may form a divalent heterocyclic (heterocyclic) group.
[0026] In general formula (1), "X" (-X-) represents a single bond; a divalent group selected from an alkylene group having 1 to 12 carbon atoms (which may have an ether bond (-O-)), an arylene group (which may be substituted with an alkylene group having 1 to 3 carbon atoms), and a divalent heterocyclic group.
[0027] Examples of the alkylene group having 1 to 12 carbon atoms include linear or branched alkylene groups such as a methylene group, ethylene group, propylene group, butylene group, isobutylene group, tert-butylene group, sec-butylene group, pentylene group, isopentylene group, neopentylene group, hexylene group, isohexylene group, 3-methylpentylene group, heptylene group, octylene group, nonylene group, decylene group, undecylene group, and dodecylene group.
[0028] The alkylene group having 1 to 12 carbon atoms and an ether bond is -(CH 2 ) p -O-(CH 2 ) p - group (a dialkylene group having an ether bond). p represents an integer of 1 to 6, and preferably an integer of 1 to 3. For example, -CH 2 CH 2 -O-CH 2 CH 2 - group (a diethylene group having an ether bond), and the like.
[0029] An arylene group is a group obtained by removing two hydrogen atoms directly bonded to carbon atoms constituting a ring from a monocyclic or bicyclic to hexacyclic aromatic hydrocarbon (e.g., benzene, naphthalene, anthracene, phenanthrene, dihydrophenanthrene, fluorene, etc.). For example, a phenylene group (-C 6 H 4 -) etc.
[0030] An arylene group substituted with an alkylene group having 1 to 3 carbon atoms (having an alkylene group having 1 to 3 carbon atoms) is a group in which two hydrogen atoms directly bonded to the carbon atoms constituting the above ring are each substituted with an alkylene group having 1 to 3 carbon atoms. For example, -(CH 2 ) q -C 6 H 4 -(CH 2 ) q - group (dimethylene group-substituted phenylene group, xylene group in which the methyl group is substituted with a methylene group), etc. q represents an integer of 1 to 3.
[0031] A divalent heterocyclic group is a group obtained by removing two hydrogen atoms directly bonded to atoms (preferably carbon atoms and / or nitrogen atoms) constituting a ring from a monocyclic or bicyclic to hexacyclic heterocyclic compound (e.g., pyridine, pyrimidine, pyrazine, pyrrolidine, piperidine, piperazine, etc.). Examples of the heterocyclic group include a divalent piperidine ring structure-containing group (hereinafter also referred to as "-(piperi)-") and a divalent piperazine ring structure-containing group (hereinafter also referred to as "-(pipera)-"). The divalent piperazine ring structure-containing group may be composed of -WX- (W represents NR) (hereinafter also referred to as "-N(pipera)-").
[0032] In general formula (1), "Y" (-Y-) represents a single bond; or a divalent group represents an ether bond (-O-), -OCO-(-OC(=O)-), -NRCO-(-(R)NC(=O)-), -CO-(-C(=O)-), or -SCO-(-SC(=O)-).
[0033] In the general formula (1), "Z" (-Z) represents an alkoxyphenyl group or an alkoxyalkyl group having an alkoxy group having 10 to 30 carbon atoms.
[0034] An alkoxyphenyl group having an alkoxy group having 10 to 30 carbon atoms refers to a phenyl group in which a hydrogen atom directly bonded to a carbon atom constituting a benzene ring is substituted with an alkoxy group having 10 to 30 carbon atoms. Examples include a dialkoxyphenyl group having two alkoxy groups bonded thereto, and a trialkoxyphenyl group having three alkoxy groups bonded thereto. Of these, a trialkoxyphenyl group is preferred.
[0035] An alkoxyalkyl group having an alkoxy group having 10 to 30 carbon atoms refers to an alkyl group in which a hydrogen atom directly bonded to a carbon atom constituting a linear or branched alkyl group having 1 to 6 carbon atoms (same as above) is substituted with an alkoxy group having 10 to 30 carbon atoms. Examples include an alkoxymethyl group, an alkoxyethyl group, an alkoxypropyl group, a dialkoxyisopropyl group, an alkoxybutyl group, an alkoxypentyl group, and an alkoxyhexyl group. Among these, a dialkoxyisopropyl group in which two alkoxy groups are bonded is preferred.
[0036] Among the pseudo solid-phase protecting groups (1), ·General formula (1wo): [Case 2] MO-(O=)CC(=O)-OXYZ (1wo) (hereinafter also referred to as "pseudo solid-phase protecting group (1wo)") and ·General formula (1wn): [C3] MO-(O=)CC(=O)-NR-XYZ (1wn) A group represented by the following formula (hereinafter also referred to as "pseudo solid-phase protecting group (1wn)") is preferred. The pseudo solid-phase protecting group (1wo) has an oxalate ester structure in which W represents O. The pseudo solid-phase protecting group (1wn) has an oxalic acid amide structure in which W represents NR.
[0037] Among the pseudo solid-phase protecting groups with oxalate structure (1wo), ·General formula (1woxe): [C4] MO-(O=)CC(=O)-O-(CH 2 ) p -O-(CH 2 ) p -YZ (p is an integer from 1 to 6) (1woxe) (hereinafter also referred to as "pseudo solid-phase protecting group (1woxe)") ·General formula (1woxp): [5] MO-(O=)CC(=O)-O-(CH 2 ) q -C6 H 4 -(CH 2 ) q -YZ (q is an integer between 1 and 3) (1woxp) (hereinafter also referred to as "pseudo solid-phase protecting group (1woxp)"), ·General formula (1wox-): [6] MO-(O=)CC(=O)-OYZ (1wox-) (hereinafter also referred to as "pseudo solid-phase protecting group (1wox-)"), ·General formula (1woxh): [7] MO-(O=)CC(=O)-O-(piperi)-YZ (1woxh) (hereinafter also referred to as "pseudo solid-phase protecting group (1woxh)") and ·General formula (1woxa): [8] MO-(O=)CC(=O)-O-(CH 2 ) r -YZ (r is an integer of 1 to 12, except for -OCO- and -NRCO-.) (1woxa) In the pseudo solid-phase protecting group (1woxe), X represents a dialkylene group having an ether bond. In the pseudo solid-phase protecting group (1woxp), X represents a dialkylene-substituted phenylene group. In the pseudo solid-phase protecting group (1wox-), X represents a single bond. In the pseudo solid-phase protecting group (1woxh), X represents a divalent piperidine ring structure-containing group (divalent heterocyclic group). In the pseudo solid-phase protecting group (1woxa), X represents an alkylene group having 1 to 12 carbon atoms, and Y represents a group other than -OCO- and -NRCO-.
[0038] Among the pseudo solid-phase protecting groups with oxalic acid amide structure (1wn), ·General formula (1wnxh): [9] MO-(O=)CC(=O)-N(pipera)-YZ (1wnxh) (hereinafter also referred to as "pseudo solid-phase protecting group (1wnxh)") and ·General formula (1wnx-): [C10] MO-(O=)CC(=O)-NR-YZ (1wnx-) A group represented by the formula (hereinafter also referred to as "pseudo solid-phase protecting group (1wnx-)") is preferred. In the pseudo solid-phase protecting group (1wnxh), -WX- (W represents NR) represents a "divalent piperazine ring structure-containing group" (divalent heterocyclic group). In the pseudo solid-phase protecting group (1wnx-), X represents a "single bond".
[0039] Specific compounds of the pseudo solid-phase protecting group (1) are shown in the following Table 1. The numbers in Table 1 correspond to the numbers of the compounds described in the following Examples, except for the numbers in parentheses.
[0040] [Table 1]
[0041] Among the specific compounds of the pseudo solid-phase protecting group (1) shown in Table 1, compounds 5, 47, 53, 58, 65, 66 and 67 are preferred, compounds 5, 47, 53, 58, 66 and 67 are more preferred, compounds 5, 47, 53 and 58 are even more preferred, and compounds 5 and 53 are even more preferred.
[0042] <Method for producing pseudo solid-phase protecting groups> The method for producing the pseudo solid-phase protecting group (1) is not particularly limited, and the group can be synthesized by a generally known method. Specific examples of the synthesis method include the methods described in the following examples.
[0043] <Protected nucleoside or protected oligonucleotide> The term "protected nucleoside" refers to a nucleoside (monomer) in which a pseudo solid-phase protecting group is bound to the 3'-position hydroxyl group. The term "protected oligonucleotide" refers to a dimer or more conjugate in which a plurality of other nucleosides or oligonucleotides (their 3'-position hydroxyl groups) are bound via phosphoric acid-containing groups by reacting a phosphoramidite with a protected nucleoside in which a pseudo solid-phase protecting group is bound to the 3'-position hydroxyl group or an oligonucleotide (its 5'-position hydroxyl group) in which a pseudo solid-phase protecting group is bound to the 3'-position hydroxyl group. The term "phosphoramidite" refers to a nucleoside phosphoramidite (monomer) or an oligonucleotide phosphoramidite (dimer or more), and refers to a compound in which a phosphorus atom is bound to the 3'-position of a nucleoside or oligonucleotide, a cyanoethoxy group, and a dialkylamino group such as a diisopropylamino group. The method for producing a protected oligonucleotide is also referred to as "elongation reaction cycle" below.
[0044] Here, in the protected nucleoside or protected oligonucleotide according to this embodiment, the 3'-position hydroxyl group is protected by binding with a pseudo solid-phase protecting group (1). The 5'-position hydroxyl group of the protected nucleoside or protected oligonucleotide is protected by binding with a temporary protecting group described later. The 2'-position of the protected nucleoside or protected oligonucleotide is a hydrogen atom (2'-deoxyribose) or a hydroxyl group (ribose) which may be protected by binding with a basic protecting group described later, and may be substituted with a methoxy group, a 2-methoxyethoxy group, or a halogen. In the case of a dimer or more of protected oligonucleotide, the 2'-positions may be the same or different from each other. The 2'-position may be bridged with the 4'-position (ribose bridged with the 2'-position and the 4'-position). In this case, the 2'-position and the 4'-position form a bond of (2'-position)-OA-(4'-position). Examples of A include an alkylene group having 1 to 6 carbon atoms (a carbon atom in the middle may be replaced with an oxygen atom or a nitrogen atom to which an alkyl group is bonded). In addition, the nucleic acid base (its amino group, carbonyl group, hydroxyl group or thiol group) of the protected nucleoside or protected oligonucleotide, and the phosphate group (hydroxyl group of a phosphodiester bond, or hydroxyl group or thiol group of a thiophosphodiester bond) of the protected oligonucleotide are protected by binding with a basic protecting group. The "nucleic acid base" is not particularly limited as long as it is used in the synthesis of nucleic acid, and examples thereof include natural bases such as cytosyl group, uracil group, thyminyl group, adenyl group, and guanyl group; modified bases such as 5-fluorouracil group, 5-methylcytosyl group, 8-oxoguanyl group, and hypoxanthinyl group.
[0045] The temporary protecting group refers to a protecting group that protects the 5'-position hydroxyl group of a protected nucleoside or protected oligonucleotide, and is a protecting group that is deprotected in an elongation reaction cycle. The deprotected 5'-position hydroxyl group is used for binding with a phosphoramidite in an elongation reaction cycle. The temporary protecting group has a structure different from that of the pseudo solid-phase protecting group (1), and therefore the function of the temporary protecting group is also different from that of the pseudo solid-phase protecting group (1). The temporary protecting group is not particularly limited, and any conventionally known protecting group can be applied. Examples of the temporary protecting group include a 4,4'-dimethoxytrityl group and a tert-butyldimethylsilyl group.
[0046] The basic protecting group refers to a protecting group that protects each group in the nucleic acid base of the protected nucleoside or protected oligonucleotide, and each group in the phosphate group of the protected oligonucleotide, and is a protecting group that is not deprotected in the extension reaction cycle. The basic protecting group protects the 2'-position hydroxy group of the protected nucleoside or protected oligonucleotide as necessary. The basic protecting group has a structure different from that of the pseudo solid-phase protecting group (1), and therefore the function of the basic protecting group is also different from that of the pseudo solid-phase protecting group (1). The basic protecting group is not particularly limited, and a conventionally known protecting group can be applied. Examples of the protecting group for the amino group in the nucleic acid base include an acetyl group, a benzoyl group, an isobutyryl group, a dimethylformamidyl group, a phenoxyacetyl group, and a 4-isopropylphenoxyacetyl group. Examples of the protecting group for the hydroxy group of the phosphate diester bond in the phosphate group, or the hydroxy group or thiol group of the thiophosphate diester bond include a cyanoethyl group, an allyl group, and a methyl group. Examples of the protecting group for the 2'-hydroxy group include an acetyl group, a benzoyl group, a phenoxyacetyl group, a tert-butyldimethylsilyl group, a triisopropylsiloxymethyl group, and a 4,4'-dimethoxytrityl group.
[0047] <Method for producing protected oligonucleotide (elongation reaction cycle)> The extension reaction cycle of the protected oligonucleotide comprises a protection step and a synthesis step. The cycle may include steps other than the above steps (other steps) as necessary.
[0048] (protection process) In the protection step, a pseudo solid-phase protecting group (1) is bound to the 3'-position hydroxy group of a nucleoside or oligonucleotide whose 5'-position hydroxy group has been protected with a temporary protecting group (hereinafter also referred to as "pseudo solid-phase protecting group (1)-bound nucleoside or oligonucleotide"). The pseudo solid-phase protecting group (1)-bound nucleoside obtained in the protection step is a protected nucleoside. In other words, the method for producing a protected nucleoside comprises only a protection step.
[0049] (synthesis process) In the synthesis process, the temporary protecting group attached to the 5' hydroxyl group of the pseudo solid-phase protecting group (1)-bound nucleoside or oligonucleotide is removed for deprotection, and then a phosphoramidite is attached to the 5' hydroxyl group, and the phosphite is oxidized or sulfurized.
[0050] The above series of steps synthesizes a dimeric protected oligonucleotide. The synthesis steps may be repeated depending on the number of cycles (chain length of the protected oligonucleotide). For example, a dimer or more (n+m)-mer, i.e., a higher-order protected oligonucleotide, is synthesized by a method of repeating the above series of steps n times (such as a method of continuously performing the series of steps in the same order in a liquid), or a method of using n-mer phosphoramidites having a predetermined length and binding them to an m-mer protected nucleoside or protected oligonucleotide. Specific methods for the extension reaction cycle include the methods described in the following examples.
[0051] Here, in the protected nucleoside or protected oligonucleotide according to this embodiment, only the pseudo solid-phase protecting group (1) can be deprotected without deprotecting the temporary protecting group and the basic protecting group by using an easy-to-handle deprotecting agent. The temporary protecting group and the basic protecting group do not have the function (selective deprotection ability) of the pseudo solid-phase protecting group (1). In this way, the pseudo solid-phase protecting group (1) can be selectively deprotected from the protected oligonucleotide by the combination of the pseudo solid-phase protecting group (1) and the deprotecting agent, so that the pseudo solid-phase protecting group (1) and the protected oligonucleotide to which it is bound can be suitably used for the production of an oligoamidite precursor.
[0052] <Method for producing oligoamidite precursor> The oligoamidite precursor refers to a protected oligonucleotide from which the pseudo solid-phase protecting group (1) bonded to the 3'-hydroxyl group has been removed.
[0053] The method for producing an oligoamidite precursor according to the present embodiment is a method for obtaining an oligoamidite precursor by selectively deprotecting the pseudo solid-phase protecting group (1) from the protected oligonucleotide according to the present embodiment. The method for producing an oligoamidite precursor includes a selective deprotection step. The method for producing an oligoamidite precursor may include steps other than those described above (other steps) as necessary.
[0054] (Selective deprotection step) In the selective deprotection step, the protected oligonucleotide is mixed with a deprotecting agent to selectively remove the pseudo solid-phase protecting group (1) bound to the 3'-hydroxy group from the protected oligonucleotide.
[0055] [Deprotection Agent] <<Method for Producing First Oligoamidite Precursor>> In the first method for producing an oligoamidite precursor, a combination of an easily handled nucleophilic agent and a base is used as a deprotecting agent.
[0056] [Nucleophiles] Examples of the nucleophilic agent include 2-cyanoethanol, 2-bromoethanol, 2,2,2-trifluoroethanol, methanol, ethylene glycol, 1,10-decanedithiol, 2-anilinoethanol, 2-aminobenzyl alcohol, and 2-aminophenol. The nucleophilic agent may be used alone or in combination of two or more (may contain at least one selected from the group consisting of the exemplified nucleophilic agents). Among the nucleophilic agents, 2-cyanoethanol, 2-bromoethanol, methanol, ethylene glycol, 2-anilinoethanol, 2-aminobenzyl alcohol, and 2-aminophenol are preferred; 2-cyanoethanol, 2-bromoethanol, methanol, and ethylene glycol are more preferred; and methanol and ethylene glycol are even more preferred. The equivalent of the nucleophilic agent in the selective deprotection step is preferably 1 to 100 equivalents, more preferably 5 to 50 equivalents, relative to the pseudo solid-phase protecting group (1).
[0057] 〔base〕 Examples of the base include triethylamine, N-methylmorpholine, N-methylimidazole, 4-dimethylaminopyridine, 4-pyrrolidinopyridine, pyridine, and dipotassium hydrogen phosphate. The base may be used alone or in combination of two or more (may contain at least one selected from the group consisting of the exemplified bases). Among the bases, triethylamine, N-methylmorpholine, N-methylimidazole, 4-dimethylaminopyridine, 4-pyrrolidinopyridine, and dipotassium hydrogen phosphate are preferred; triethylamine, 4-dimethylaminopyridine, 4-pyrrolidinopyridine, and dipotassium hydrogen phosphate are more preferred; and triethylamine, 4-dimethylaminopyridine, and 4-pyrrolidinopyridine are even more preferred. The equivalent of the base in the selective deprotection step is preferably 0.001 to 3 equivalents, more preferably 0.001 to 1.5 equivalents, relative to the pseudo solid-phase protecting group (1).
[0058] Preferred combinations of nucleophiles and bases include a combination of 2-cyanoethanol and at least one of triethylamine, 4-dimethylaminopyridine, 4-pyrrolidinopyridine, and dipotassium hydrogen phosphate; a combination of methanol and 4-pyrrolidinopyridine; a combination of ethylene glycol and 4-pyrrolidinopyridine, and the like.
[0059] <<Method for Producing Second Oligoamidite Precursor>> In the second method for producing an oligoamidite precursor, an easily handled aliphatic amino alcohol is used as a deprotecting agent.
[0060] [Aliphatic amino alcohol] Examples of the aliphatic amino alcohol include 2-(methylamino)ethanol, 2-[(hydroxymethyl)amino]ethanol, and diethanolamine. The aliphatic amino alcohol may be used alone or in combination of two or more (including at least one selected from the group consisting of the exemplified aliphatic amino alcohols). Among the aliphatic amino alcohols, 2-(methylamino)ethanol is preferred. The equivalent of the aliphatic amino alcohol in the selective deprotection step is preferably 1 to 5 equivalents, more preferably 1 to 3 equivalents, relative to the pseudo solid-phase protecting group (1).
[0061] In the selective deprotection step, the protected oligonucleotide and the deprotecting agent are mixed in a solvent. The solvent is preferably a low polarity solvent that has high solubility for the protected oligonucleotide and the deprotecting agent, and examples thereof include halogen-based solvents such as chloroform, dichloromethane, and 1,2-dichloroethane; aromatic solvents such as benzene, toluene, xylene, and mesitylene; ester-based solvents such as ethyl acetate and isopropyl acetate; aliphatic solvents such as hexane, pentane, heptane, octane, nonane, and cyclohexane; and ether-based solvents such as tetrahydrofuran, diethyl ether, cyclopentyl methyl ether, and tert-butyl methyl ether. The solvents may be used alone or in combination of two or more.
[0062] The reaction temperature in the selective deprotection step is preferably about 5 to 40° C. The reaction time in the selective deprotection step is preferably within 24 hours, and the shorter the better, e.g., within 20 hours, within 10 hours, within 8 hours, within 5 hours, within 3 hours, within 1 hour, within 30 minutes, within 10 minutes, etc. The reaction time refers to the time at which the yield of selective deprotection (production rate of oligoamidite precursor) is preferably 70% or more, more preferably 80% or more, and even more preferably 90% or more.
[0063] By the selective deprotection step described above, an oligoamidite precursor is obtained from the protected oligonucleotide. The selective deprotection step may be combined with the protection step and the synthesis step in the extension reaction cycle of the protected oligonucleotide to form a series of steps. Specific methods for the selective deprotection step include those described in the following examples.
[0064] As described above in detail, the pseudo solid-phase protecting group (1) according to this embodiment is deprotected more quickly than the conventional pseudo solid-phase protecting group under all general deprotection conditions for oligonucleotide synthesis, and therefore can be used in oligonucleotide synthesis. The pseudo solid-phase protecting group (1) can be easily separated from secondary raw materials such as amidite monomers by filtration or the like by adding a polar solvent (acetonitrile, methanol, etc.) in liquid-phase synthesis. In addition, according to the pseudo solid-phase protecting group (1), the protected oligonucleotide having the pseudo solid-phase protecting group (1), and the method for producing an oligoamidite precursor using the protected oligonucleotide according to this embodiment, the pseudo solid-phase protecting group (1) can be selectively removed using a combination of an easy-to-handle nucleophile and a base or an aliphatic amino alcohol as a deprotecting agent used in the selective deprotection step without using harmful or dangerous reagents such as conventional heavy metals, hydrogen gas, and lithium borohydride, and therefore can be suitably used for mass production of oligoamidite precursors. Therefore, the pseudo solid-phase protecting group (1) is useful for establishing a method for mass production of oligonucleotides or oligoamidites.
[0065] <Other embodiments> The pseudo solid-phase protecting group (1) according to the above embodiment, and the method for producing a protected oligonucleotide and an oligoamidite precursor using the same can be applied not only to DNA synthesis but also to RNA synthesis (e.g., synthesis of an RNA-type oligoamidite in which the 2'-hydroxyl group is protected with a TBDMS group). EXAMPLES
[0066] The present disclosure will be described below based on examples. Note that the present disclosure is not limited to the following examples, and the following examples can be modified or changed based on the spirit of the present disclosure, and are not excluded from the scope of the present disclosure.
[0067] (NMR spectrum) 1 H, 13 C and 31 P-NMR spectra were obtained using a Bruker Biospin AVANCE III 400 Nano-Bay ( 1 H: 400MHz, 13 C: 100MHz, 31 P: 162MHz. The internal standard was tetramethylsilane ( 1 H and 13 C: 0 ppm) or triethyl phosphate ( 31 P: 0.20 ppm) was used.
[0068] (mass spectrometry) Mass spectrometry was performed using a JEOL JMS-S3000.
[0069] (Explanation of abbreviations) THF: Tetrahydrofuran ·MTBE: tert-butyl methyl ether HBTU: 1-[bis(dimethylamino)methylene]-1H-benzotriazolium 3-oxide hexafluorophosphate COMU: (1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate BTT: 5-(benzylthio)-1H-tetrazole ·TBHP: tert-butyl hydroperoxide.
[0070] Example 1 (Synthesis of precursor of pseudo solid-phase protecting group): Synthesis of compound 3
[0071] [ka]
[0072] Step 1-1: Synthesis of Compound 2 Compound 1 (12.0 g, 65.2 mmol), 1-bromooctadecane (71.6 g, 215 mmol), potassium carbonate (54.0 g, 391 mmol) and sodium iodide (977 mg, 6.52 mmol) were suspended in N,N-dimethylformamide (230 g) under a nitrogen atmosphere and stirred at 85 °C for 18 hours. The reaction solution was added to water (1300 g) and the precipitated solid was filtered. The obtained solid was washed with water and methanol to obtain wet crystals of compound 2 (89.0 g) as a slightly brown solid. The obtained wet crystals were used in the next step as they were. Note that the wet crystals refer to the crystals before drying after crystallization and separation from the mother liquor, and are distinguished from the dry crystals, which are the crystals after drying.
[0073] Step 1-2: Synthesis of compound 3 Under a nitrogen atmosphere, wet crystals of compound 2 (89.0 g) were suspended in a mixture of methanol (9.8 g) and THF (290 g), and 24% aqueous sodium hydroxide solution (54.1 g, 325 mmol) was added at room temperature and refluxed for 16.5 hours. THF (143 g) was removed by concentration under normal pressure, and concentrated hydrochloric acid (48 g) was added at room temperature. The reaction solution was added to a mixture of water (670 g) and acetonitrile (1000 g), and the precipitated solid was filtered. The obtained solid was washed with water and acetonitrile, and then dried under reduced pressure at 35 °C to obtain compound 3 (63.6 g, 105% yield from compound 1) as a pale yellowish white solid. 1 H-NMR (400 MHz, CDCl 3):δ 0.80-0.95(m, 9H), 1.15-1.55(m, 90H), 1.68-1.90(m, 6H), 3.92-4.15(m, 6H), 7.32(s, 2H). 13 C-NMR (100 MHz, CDCl 3 ):δ 14.1, 22.7, 22.9, 26.1, 26.1, 29.2, 29.4, 29.4, 29.6, 29.7, 29.7, 29.7, 30.4, 32.0, 69.4, 73.6, 108.9, 123.7, 143.5, 153.0, 171.1.
[0074] Example 2 (Synthesis of pseudo solid-phase protecting group (diethylene glycol type)): Synthesis of compound 5
[0075] [ka]
[0076] Step 2-1: Synthesis of compound 4 Under a nitrogen atmosphere, compound 3 (20.0 g, 21.6 mmol), diethylene glycol (34.4 g, 324 mmol) and N-methylimidazole (3.54 g, 43.1 mmol) were suspended in THF (190 g), and HBTU (12.3 g, 32.4 mmol) and 4-dimethylaminopyridine (526 mg, 4.31 mmol) were added at room temperature and stirred at room temperature for 46 hours. The reaction solution was added to acetonitrile (680 g) and the precipitated solid was filtered. The obtained solid was washed with acetonitrile and dried under reduced pressure at room temperature to obtain compound 4 (21.0 g, yield 96.2%) as a pale yellowish white solid. 1 H-NMR (400 MHz, CDCl 3):δ 0.80-0.95(m, 9H), 1.15-1.55(m, 90H), 1.70-1.85(m, 6H), 3.58-3.70(m, 2H), 3.72-3.80(m, 2H), 3.80-3.88(m, 2H), 3.94-4.10(m, 6H), 4.39-4.54(m, 2H), 7.26(s, 2H). 13 C-NMR (100 MHz, CDCl 3 ):δ 14.1, 22.7, 26.1, 26.1, 29.3, 29.4, 29.4, 29.6, 29.7, 29.7, 29.7, 30.3, 31.9, 61.8, 64.0, 69.2, 69.3, 72.4, 73.5, 108.1, 124.5, 142.6, 152.9, 166.5.
[0077] Step 2-2: Synthesis of compound 5 Under a nitrogen atmosphere, a solution of compound 4 (20.0 g, 19.7 mmol) in dichloromethane (200 g) was added dropwise to a solution of oxalyl chloride (7.50 g, 59.1 mmol) in dichloromethane (100 g) at room temperature over 15 minutes, and the mixture was stirred at room temperature for 30 minutes. At room temperature, the reaction solution was added dropwise to a mixture of 10% aqueous potassium bicarbonate solution (158 g) and dichloromethane (52 g) over 10 minutes, and the precipitated solid was filtered. The obtained solid was washed with water and dichloromethane, and then dried under reduced pressure at room temperature to obtain compound 5 (20.6 g, yield 92.8%) as a pale yellowish white solid. 1 H-NMR (400 MHz, CDCl 3 , 50 ℃):δ 0.80-0.98(m, 9H), 1.16-1.54(m, 90H), 1.62-1.85(m, 6H), 3.65-3.85(m, 4H), 3.85-4.05(m, 6H), 4.06-4.29(m, 2H), 4.31-4.57(m, 2H), 7.17(brs, 2H). 13 C-NMR (100 MHz, CDCl 3):δ 14.1, 22.7, 26.2, 26.3, 29.4, 29.6, 29.6, 29.7, 29.8, 29.8, 29.8, 29.8, 29.8, 30.5, 32.0, 63.8, 69.0, 69.3, 69.4, 73.5, 108.5, 124.5, 142.9, 152.9, 162.2, 165.0, 166.4.
[0078] Example 3 (Synthesis of a T-terminal protected oligonucleotide dimer): Synthesis of compound 10
[0079] [ka]
[0080] Step 3-1: Synthesis of Compound 7 (Protected Nucleoside) Under a nitrogen atmosphere, compound 5 (9.00 g, 7.99 mmol), compound 6 (5.66 g, 10.4 mmol), 2,6-lutidine (3.00 g, 28.0 mmol) and 4-dimethylaminopyridine (195 mg, 1.60 mmol) were suspended in THF (71 g), and COMU (9.25 g, 21.6 mmol) was added at room temperature and stirred at room temperature for 3 hours. The reaction solution was filtered, and the filtrate was added to acetonitrile (320 g) and the precipitated solid was filtered. The obtained solid was washed with acetonitrile and dried under reduced pressure at room temperature to obtain compound 7 (12.1 g, yield 93.8%) as a slightly brownish white solid. 1 H-NMR (400 MHz, CDCl 3):δ 0.80-0.95(m, 6H), 1.15-1.55(m, 93H), 1.68-1.89(m, 6H), 2.41-2.70(m, 2H), 3.41-3.60(m, 2H), 3.74-3.92(m, 10H), 3.93-4.09(m, 6H), 4.20-4.28(m, 1H), 4.37-4.55(m, 4H), 5.49-5.64(m, 1H), 6.42-6.55(m, 1H), 6.79-6.91(m, 4H), 7.20-7.35(m, 9H), 7.35-7.44(m, 2H), 7.56-7.67(m, 1H), 8.33(brs, 1H). 13 C-NMR (100 MHz, CDCl 3 ):δ 11.7, 14.1, 22.7, 26.1, 26.1, 29.3, 29.4, 29.4, 29.6, 29.7, 29.7, 30.4, 31.9, 37.7, 55.3, 63.5, 63.8, 66.1, 68.3, 69.2, 69.4, 73.5, 78.3, 83.5, 84.3, 87.3, 108.1, 111.8, 113.4, 124.4, 127.3, 128.1, 128.1, 130.0, 130.1, 135.0, 135.1, 135.2, 142.6, 144.1, 150.1, 152.8, 157.0, 157.0, 158.8, 158.8, 163.3, 166.4.
[0081] Step 3-2: Synthesis of compound 8 Under a nitrogen atmosphere, pyrrole (1.68 g, 25.0 mmol) and dichloroacetic acid (1.86 g, 14.4 mmol) were added to a solution of compound 7 (11.6 g, 7.19 mmol) in dichloromethane (290 g) at room temperature, and the mixture was stirred at room temperature for 2 hours. After adding 2,6-lutidine (1.93 g, 18.0 mmol), the reaction solution was added to acetonitrile (430 g), and the precipitated solid was filtered and washed with acetonitrile. The mixture was dried under reduced pressure at room temperature to obtain compound 8 (9.32 g, 98.8% yield) as a slightly brownish white solid. 1H-NMR (400 MHz, CDCl 3 ):δ 0.80-0.95(m, 9H), 1.20-1.55(m, 90H), 1.65-1.87(m, 6H), 1.87-1.98(m, 3H), 2.37-2.64(m, 2H), 3.75-4.10(m, 12H), 4.13-4.21(m, 1H), 4.40-4.54(m, 4H), 5.35-5.45(m, 1H), 6.14-6.24(m, 1H), 7.25(s, 1H), 7.44-7.52(m, 1H), 8.59(brs, 1H). 13 C-NMR (100 MHz, CDCl 3 ):δ 12.6, 14.1, 22.7, 26.1, 26.1, 29.4, 29.4, 29.4, 29.6, 29.7, 29.7, 30.3, 31.9, 36.7, 62.5, 63.7, 66.0, 68.2, 69.2, 69.3, 73.6, 77.9, 84.7, 86.9, 108.1, 111.5, 124.6, 136.8, 142.3, 150.3, 152.8, 157.0, 157.0, 163.4, 166.4.
[0082] Step 3-3: Synthesis of compound 10 Compound 8 (4.40 g, 3.35 mmol), compound 9 (3.92 g, 4.70 mmol) and molecular sieve 3A (0.80 g) were suspended in dichloromethane (44 g) under a nitrogen atmosphere, BTT (752 mg, 4.69 mmol) was added at room temperature, and the mixture was stirred at room temperature for 2 hours. 5.1 M TBHP / n-decane solution (1.32 mL, 6.70 mmol) was added at room temperature and stirred for 2 hours, after which the reaction solution was filtered, and the filtrate was added to acetonitrile (200 g) to filter the precipitated solid. The obtained solid was washed with acetonitrile and then dried under reduced pressure at room temperature to obtain compound 10 (6.46 g, yield 93.5%) as a slightly brownish white solid. 1 H-NMR (400 MHz, CDCl 3):δ 0.80-0.96(m, 9H), 1.17-1.54(m, 90H), 1.68-1.95(m, 9H), 2.30-2.60(m, 3H), 2.62-2.84(m, 2H), 2.90-3.06(m, 1H), 3.34-3.59(m, 2H), 3.72-3.92(m, 10H), 3.94-4.07(m, 6H), 4.11-4.53(m, 10H), 5.09-5.23(m, 1H), 5.38-5.55(m, 1H), 6.14-6.35(m, 2H), 6.79-6.93(m, 4H), 7.19-7.42(m, 13H), 7.45-7.56(m, 2H), 7.56-7.66(m, 1H), 7.84-7.98(m, 2H), 8.07-8.19(m, 1H), 8.63-9.00(m, 2H). 31 P-NMR (162 MHz, CDCl 3 ):δ -1.66, -1.57. MALDI-TOF / MS: [M+Na] + 2082.2052.
[0083] Example 4 (Selective deprotection of pseudo solid-phase protecting group from T-terminal dimer protected oligonucleotide): Synthesis of compound 11
[0084] [ka]
[0085] Under a nitrogen atmosphere, a solution of compound 10 (1.00 g, 0.485 mmol), ethylene glycol (452 mg, 6.28 mmol) and 4-pyrrolidinopyridine (14.4 mg, 97.2 μmol) in THF (6.5 g) was stirred at room temperature for 3 hours. The reaction solution was added to MTBE (21 g) and the precipitated solid was filtered. The obtained solid was washed with MTBE and then dried under reduced pressure at room temperature to obtain compound 11 (417 mg, 86.7% yield) as a white solid. 1 H-NMR (400 MHz, CDCl 3):δ 1.86-1.90(m, 3H), 2.17-2.50(m, 3H), 2.67-2.80(m, 2H), 2.95-3.09(m, 1H), 3.40-3.54(m, 2H), 3.74-3.84(m, 6H), 4.04-4.45(m, 6H), 4.46-4.61(m, 1H), 5.03-5.22(m, 1H), 6.16-6.30(m, 2H), 6.80-6.92(m, 4H), 7.20-7.44(m, 11H), 7.45-7.54(m, 2H), 7.54-7.64(m, 1H), 7.89-8.02(m, 2H), 8.05-8.16(m, 1H), 9.06-9.84(m, 2H). 31 P-NMR (162 MHz, CDCl 3 ):δ -1.94, -1.13. MALDI-TOF / MS: [M+Na] + 1013.3062.
[0086] Example 5 (Synthesis of a C-terminal protected dimer oligonucleotide): Synthesis of compound 16
[0087] [ka]
[0088] Step 5-1: Synthesis of compound 13 (protected nucleoside) Under a nitrogen atmosphere, compound 5 (10.0 g, 8.88 mmol), compound 12 (9.57 g, 15.1 mmol), 2,6-lutidine (1.90 g, 17.7 mmol) and 4-dimethylaminopyridine (217 mg, 1.78 mmol) were suspended in THF (79 g), and COMU (9.51 g, 22.2 mmol) was added at room temperature and stirred at room temperature for 2 hours. The reaction solution was filtered, and the filtrate was added to a mixture of acetonitrile (220 g) and water (280 g), and the precipitated solid was filtered. The obtained solid was washed with acetonitrile and dried under reduced pressure at room temperature to obtain compound 13 (13.4 g, yield 88.5%) as a white solid. 1H-NMR (400 MHz, CDCl 3 ):δ 0.80-0.97(m, 9H), 1.18-1.55(m, 90H), 1.66-1.89(m, 6H), 2.33-2.49(m, 1H), 2.89-3.05(m, 1H), 3.45-3.60(m, 2H), 3.74-3.82(m, 6H), 3.82-3.92(m, 4H), 3.94-4.08(m, 4H), 4.32-4.41(m, 1H), 4.42-4.54(m, 4H), 5.42-5.58(m, 1H), 6.30-6.41(m, 1H), 6.78-6.94(m, 4H), 7.20-7.42(m, 12H), 7.48-7.58(m, 2H), 7.59-7.66(m, 1H), 7.80-7.99(m, 2H), 8.07-8.21(m, 1H), 8.66(brs, 1H). 13 C-NMR (100 MHz, CDCl 3 ): δ 14.1, 22.7, 26.1, 26.1, 29.3, 29.4, 29.5, 29.6, 29.7, 29.7, 30.4, 31.9, 39.3, 55.2, 55.2, 63.0, 63.8, 66.1, 68.3, 69.2, 69.4, 73.5, 77.5, 84.3, 87.2, 87.3, 96.4, 108.1, 113.4, 113.4, 124.5, 127.2, 127.5, 128.0, 128.1, 129.1, 130.0, 130.0, 133.0, 133.2, 135.0, 135.1, 142.5, 143.9, 144.3, 152.8, 156.9, 156.9, 158.8, 158.8, 162.2, 166.4.
[0089] Process 5-2: Synthesis of Compound 14 According to the method of Process 3-2, compound 13 (12.0 g, 7.04 mmol) and compound 14 (9.66 g, yield 98.0%) were obtained as a white-gray solid. 1 H-NMR (400 MHz, CDCl 3):δ 0.80-0.96(m, 9H), 1.16-1.56(m, 90H), 1.69-1.87(m, 6H), 2.49-2.63(m, 1H), 2.69-2.80(m, 1H), 3.79-4.07(m, 12H), 4.26-4.32(m, 1H), 4.42-4.52(m, 4H), 5.41-5.51(m, 1H), 6.18-6.30(m, 1H), 7.25(s, 1H), 7.46-7.69(m, 4H), 7.83-7.96(m, 2H), 8.22-8.33(m, 1H),8.85(brs, 1H). 13 C-NMR (100 MHz, CDCl 3 ):δ 14.1, 22.7, 26.1, 26.1, 29.4, 29.4, 29.5, 29.6, 29.7, 29.7, 30.3, 31.9, 38.2, 63.4, 63.7, 66.0, 68.2, 69.2, 69.3, 73.6, 78.0, 85.6, 88.9, 97.0, 108.1, 124.6, 127.6, 129.1, 132.9, 133.3, 142.3, 145.7, 152.8, 157.0, 157.0, 162.5, 166.4.
[0090] Step 5-3: Synthesis of compound 16 According to the method of step 3-3, compound 16 (5.82 g, yield 93.9%) was obtained as a slightly yellow solid from compound 14 (4.00 g, 2.86 mmol) and compound 15 (3.43 g, 4.00 mmol). 1 H-NMR (400 MHz, CDCl 3):δ 0.80-0.96(m, 9H), 1.16-1.56(m, 90H), 1.67-1.87(m, 6H), 2.30-2.47(m, 1H), 2.61-2.98(m, 4H), 3.17-3.35(m, 1H), 3.37-3.56(m, 2H), 3.69-3.90(m, 10H), 3.93-4.07(m, 6H), 4.15-4.54(m, 10H), 5.25-5.39(m, 1H), 5.41-5.56(m, 1H), 6.19-6.33(m, 1H), 6.43-6.59(m, 1H), 6.72-6.85(m, 4H), 7.15-7.32(m, 9H), 7.33-7.41(m, 2H), 7.43-7.66(m, 7H), 7.77-7.92(m, 2H), 7.95-8.10(m, 3H), 8.14-8.26(m, 1H), 8.60-8.69(m, 1H), 8.70-8.98(m, 1H), 9.00-9.18(m, 1H). 31 P-NMR (162 MHz, CDCl 3 ):δ -1.32, -1.13. MALDI-TOF / MS: [M+Na] + 2195.2462.
[0091] Example 6 (Selective deprotection of pseudo solid-phase protecting group from C-terminal dimer protected oligonucleotide): Synthesis of compound 17
[0092] [ka]
[0093] According to the method of Example 4, compound 17 (475 mg, yield 94.8%) was obtained as a white solid from compound 16 (1.00 g, 0.460 mmol), ethylene glycol (428 mg, 6.90 mmol) and 4-pyrrolidinopyridine (10.2 mg, 68.8 μmol). 1 H-NMR (400 MHz, CDCl 3):δ 2.20-2.34(m, 1H), 2.61-2.91(m, 4H), 3.10-3.30(m, 1H), 3.35-3.54(m, 2H), 3.69-3.80(m, 6H), 4.11-4.59(m, 7H), 5.26-5.39(m, 1H), 6.15-6.26(m, 1H), 6.43-6.58(m, 1H), 6.73-6.85(m, 4H), 7.16-7.30(m, 7H), 7.33-7.63(m, 9H), 7.80-7.91(m, 2H), 7.96-8.05(m, 2H), 8.05-8.15(m, 1H), 8.17-8.27(m, 1H), 8.59-8.69(m, 1H), 8.93-9.42(m, 2H). 31 P-NMR (162 MHz, CDCl 3 ):δ -1.06, -0.95. MALDI-TOF / MS: [M+Na] + 1126.3422.
[0094] Example 7 (Synthesis of A-terminal protected oligonucleotide dimer): Synthesis of compound 22
[0095] [ka]
[0096] Step 7-1: Synthesis of Compound 19 (Protected Nucleoside) According to the method of step 3-1, compound 19 (3.65 g, yield 79.5%) was obtained as a white solid from compound 5 (3.00 g, 2.66 mmol) and compound 18 (2.00 g, 3.04 mmol). 1 H-NMR (400 MHz, CDCl 3):δ 0.80-0.97(m, 6H), 1.14-1.40(m, 84H), 1.40-1.55(m, 6H), 1.66-1.89(m, 6H), 2.60-2.69(m, 1H), 3.12-3.26(m, 1H), 3.43-3.55(m, 2H), 3.71-3.82(m, 6H), 3.82-3.94(m, 4H), 3.94-4.10(m, 6H), 4.32-4.44(m, 1H), 4.44-4.55(m, 4H), 5.62-5.74(m, 1H), 6.47-6.57(m, 1H), 6.73-6.88(m, 4H), 7.16-7.35(m, 9H), 7.36-7.43(m, 2H), 7.49-7.58(m, 2H), 7.58-7.67(m, 1H), 7.97-8.10(m, 2H), 8.19(s, 1H), 8.71(brs, 1H), 9.03(brs, 1H). 13 C-NMR (100 MHz, CDCl 3 ):δ 14.1, 22.7, 26.1, 26.1, 29.3, 29.4, 29.4, 29.6, 29.7, 29.7, 30.4, 31.9, 37.4, 55.2, 63.3, 63.8, 66.1, 68.3, 69.2, 69.4, 73.5, 78.1, 84.0, 84.7, 86.8, 108.1, 113.2, 123.4, 124.4, 127.0, 127.9, 128.0, 128.1, 128.9, 130.0, 130.0, 130.8, 132.8, 133.6, 135.4, 135.4, 141.4, 142.6, 144.3, 149.6, 151.5, 152.7, 152.9, 156.8, 157.1, 158.61, 158.6, 164.5, 166.4.
[0097] Step 7-2: Synthesis of compound 20 According to the method of step 3-2, compound 20 (1.91 g, yield 92.7%) was obtained as a white-gray solid from compound 19 (2.50 g, 1.45 mmol). 1H-NMR (400 MHz, CDCl 3 ):δ 0.81-0.94(m, 6H), 1.16-1.39(m, 84H), 1.41-1.53(m, 6H), 1.68-1.87(m, 6H), 2.50-2.65(m, 1H), 3.20-3.35(m, 1H), 3.81-4.07(m, 12H), 4.31-4.40(m, 1H), 4.40-4.56(m, 4H), 5.65-5.77(m, 1H), 6.35-6.45(m, 1H), 7.26(s, 2H), 7.49-7.58(m, 2H), 7.58-7.67(m, 1H), 7.99-8.09(m, 2H), 8.16(s, 1H), 8.79(s, 1H), 9.14(brs, 1H). 13 C-NMR (100 MHz, CDCl 3 ):δ 14.1, 22.7, 26.1, 26.1, 29.3, 29.4, 29.4, 29.6, 29.7, 29.7, 30.3, 31.9, 34.5, 63.2, 63.8, 66.1, 68.3, 69.2, 69.3, 73.6, 79.2, 86.8, 87.6, 108.1, 124.4, 124.6, 127.9, 128.9, 133.0, 133.4, 142.6, 142.7, 150.4, 150.6, 152.2, 152.9, 156.9, 157.1, 164.5, 166.4.
[0098] Step 7-3: Synthesis of compound 22 According to the method of step 3-3, compound 22 (2.00 g, yield 87.0%) was obtained as a slightly yellow solid from compound 20 (1.50 g, 1.05 mmol) and compound 21 (1.24 g, 1.40 mmol). 1 H-NMR (400 MHz, CDCl 3):δ 0.78-0.98(m, 9H), 0.98-1.54(m, 96H), 1.67-1.88(m, 6H), 2.36-2.51(m, 1H), 2.52-2.96(m, 5H), 3.20-3.49(m, 3H), 3.70-3.79(m, 6H), 3.80-3.90(m, 4H), 3.94-4.55(m, 16H), 5.20-5.38(m, 1H), 5.69-5.83(m, 1H), 6.01-6.13(m, 1H), 6.44-6.56(m, 1H), 6.72-6.85(m, 4H), 7.11-7.30(m, 9H), 7.31-7.39(m, 2H), 7.40-7.53(m, 2H), 7.53-7.64(m, 1H), 7.66-7.73(m, 1H), 7.83-8.04(m, 2H), 8.22-8.34(m, 1H), 8.74-8.88(m, 1H), 9.13-9.34(m, 1H), 11.80-12.12(m, 1H). 31 P-NMR (162 MHz, CDCl 3 ):δ -1.54, -1.13. MALDI-TOF / MS: [M+Na] + 2201.2564.
[0099] Example 8 (Selective deprotection of pseudo solid-phase protecting group from A-terminal dimer oligonucleotide protector): Synthesis of compound 23
[0100] [ka]
[0101] According to the method of Example 4, compound 23 (507 mg, yield 99.6%) was obtained as a white solid from compound 22 (1.00 g, 0.459 mmol), ethylene glycol (427 mg, 6.88 mmol) and 4-pyrrolidinopyridine (10.2 mg, 68.8 μmol). 1 H-NMR (400 MHz, CDCl 3):δ 1.02-1.19(m, 6H), 2.38-3.15(m, 7H), 3.24-3.34(m, 2H), 3.68-3.80(m, 6H), 3.96-4.52(m, 6H), 4.87-5.06(m, 1H), 5.17-5.47(m, 1H), 6.01-6.13(m, 1H), 6.41-6.55(m, 1H), 6.70-6.85(m, 4H), 7.12-7.41(m, 9H),7.41-7.55(m, 2H), 7.55-7.71(m, 2H), 7.85-8.06(m, 2H), 8.20-8.44(m, 1H), 8.72-8.87(m, 1H), 9.11-9.32(m, 1H), 9.50-10.14(m, 1H), 11.87-12.09(m, 1H). 31 P-NMR (162 MHz, CDCl 3 ):δ -1.57, -0.94. MALDI-TOF / MS: [M+Na] + 1132.3650.
[0102] Example 9 (Synthesis of a G-terminal protected oligonucleotide dimer): Synthesis of compound 28
[0103] [ka]
[0104] Step 9-1: Synthesis of Compound 25 (Protected Nucleoside) According to the method of step 5-1, compound 25 (12.6 g, yield 91.9%) was obtained as a white solid from compound 5 (9.00 g, 7.99 mmol) and compound 24 (7.67 g, 12.0 mmol). 1 H-NMR (400 MHz, CDCl 3):δ 0.81-0.95(m, 12H), 1.00-1.06(m, 3H), 1.16-1.53(m, 90H), 1.66-1.84(m, 6H), 1.89-1.99(m, 1H), 2.52-2.63(m, 1H), 3.12-3.35(m, 2H), 3.41-3.53(m, 1H), 3.71-3.90(m, 10H), 3.92-4.07(m, 6H), 4.20-4.30(m, 1H), 4.41-4.55(m, 4H), 5.62-5.75(m, 1H), 6.09-6.18(m, 1H), 6.73-6.88(m, 4H), 7.13-7.39(m, 9H), 7.43-7.52(m, 2H), 7.78(s, 1H), 8.11(brs, 1H). 13 C-NMR (100 MHz, CDCl 3 ): δ 14.1, 18.9, 22.7, 26.1, 26.1, 29.3, 29.4, 29.4, 29.6, 29.7, 29.7, 30.3, 31.9, 36.2, 37.2, 55.2, 63.4, 64.0, 66.2, 68.3, 69.3, 69.3, 73.6, 77.9, 83.7, 84.4, 86.5, 108.2, 113.3, 113.3, 122.3, 124.3, 127.2, 128.00, 128.1, 129.1, 129.9, 135.4, 135.7, 137.7, 142.8, 144.6, 147.3, 148.0, 152.9, 155.4, 156.9, 157.1, 158.8, 166.7, 178.4.
[0105] Process 9-2: Synthesis of Compound 26 According to the method of Process 3-2, compound 25 (11.0 g, 6.44 mmol) and compound 26 (9.13 g, yield 100%) were obtained as a white-grey solid. 1 H-NMR (400 MHz, CDCl 3):δ 0.81-0.96(m, 9H), 1.16-1.54(m, 96H), 1.67-1.89(m, 6H), 2.45-2.59(m, 1H), 2.66-2.80(m, 2H), 2.99-3.13(m, 1H), 3.81-4.08(m, 12H), 4.23-4.33(m, 1H), 4.40-4.57(m, 4H), 5.54-5.67(m, 1H), 6.16-6.24(m, 1H), 7.25(s, 1H), 7.87(s, 1H), 9.02(brs, 1H), 12.16(brs, 1H). 13 C-NMR (100 MHz, CDCl 3 ):δ 14.1, 18.9, 22.7, 26.1, 26.1, 29.3, 29.4, 29.4, 29.6, 29.7, 29.7, 30.3, 31.9, 36.2, 37.4, 82.8, 63.9, 66.2, 68.3, 69.3, 69.3, 73.6, 78.8, 85.8, 86.2, 108.2, 122.5, 124.4, 131.3, 138.6, 142.6, 147.1, 147.8, 152.9, 155.1, 157.0, 157.1, 166.6.
[0106] Step 9-3: Synthesis of compound 28 According to the method of step 3-3, compound 28 (5.24 g, yield 87.0%) was obtained as a slightly yellow solid from compound 26 (4.00 g, 2.84 mmol) and compound 27 (2.96 g, 3.97 mmol). 1 H-NMR (400 MHz, CDCl 3):δ 0.81-0.97(m, 9H), 1.06-1.53(m, 96H), 1.68-1.89(m, 9H), 2.31-2.81(m, 3H), 3.24-3.59(m, 3H), 3.72-3.93(m, 10H), 3.93-4.06(m, 6H), 4.10-4.55(m, 9H), 4.61-4.83(m, 1H), 5.03-5.26(m, 1H), 5.48-5.79(m, 1H), 6.12-6.24(m, 1H), 6.28-6.51(m, 1H), 6.76-6.94(m, 4H), 7.13-7.43(m, 11H), 7.43-7.61(m, 1H), 7.65-7.85(m, 1H), 8.37-9.08(m, 1H), 9.98-10.38(m, 1H), 11.94-12.41(m, 1H). 31 P-NMR (162 MHz, CDCl 3 ):δ -2.96, -2.35. MALDI-TOF / MS: [M+Na] + 2088.2350.
[0107] Example 10 (Selective deprotection of pseudo solid-phase protecting group from G-terminal dimer protected oligonucleotide): Synthesis of compound 29
[0108] [ka]
[0109] According to the method of Example 4, compound 29 (450 mg, yield 93.4%) was obtained as a white solid from compound 28 (1.00 g, 0.484 mmol), ethylene glycol (451 mg, 6.27 mmol) and 4-pyrrolidinopyridine (14.3 mg, 96.5 μmol). 1 H-NMR (400 MHz, CDCl 3):δ 1.09-1.23(m, 6H), 1.34-1.46(m, 3H), 2.26-2.91(m, 7H), 3.27-3.54(m, 2H), 3.67-3.84(m, 6H), 4.04-4.52(m, 6H), 4.67-4.87(m, 1H), 5.02-5.16(m, 1H), 6.14-6.42(m, 2H), 6.73-6.90(m, 4H), 7.13-7.39(m, 9H), 7.45-7.58(m, 1H), 7.83-7.97(m, 1H), 9.51-10.85(m, 2H), 12.14-12.51(m, 1H). 31 P-NMR (162 MHz, CDCl 3 ):δ -2.51, -2.02. MALDI-TOF / MS: [M+Na] + 1019.3275.
[0110] Example 11 (Synthesis of a tetramer protected oligonucleotide): Synthesis of compound 33
[0111] [ka]
[0112] Step 11-1: Synthesis of compound 30 According to the method of step 3-2, compound 30 (14.3 g, yield 98.6%) was obtained as a slightly brownish white solid from compound 10 (17.0 g, 8.25 mmol). 1 H-NMR (400 MHz, CDCl 3):δ 0.77-0.99(m, 9H), 1.17-1.55(m, 90H), 1.68-1.98(m, 9H), 2.39-2.68(m, 3H), 2.73-2.90(m, 3H), 3.73-4.10(m, 12H), 4.21-4.57(m, 10H), 5.14-5.32(m, 1H), 5.42-5.60(m, 1H), 6.07-6.32(m, 2H), 7.19-7.34(m, 3H), 7.42-7.68(m, 4H), 7.83-8.00(m, 2H), 8.20-8.37(m, 1H), 8.93-9.57(m, 2H). 31 P-NMR (162 MHz, CDCl 3 ):δ -1.57, -1.44. MALDI-TOF / MS:[M+Na] + 1780.0669.
[0113] Project 11-2: Synthesis of Compound 31 The method of Process 3-3 was to obtain Compound 30 (13.0 g, 7.39 mmol), Compound 27 (7.71 g, 10.4 mmol), and Compound 31 (17.5 g, yield 97.8%) as a slightly brownish white solid. 1 H-NMR (400 MHz, CDCl 3 ):δ 0.81-0.96(m, 9H), 1.17-1.53(m, 90H), 1.68-1.97(m, 12H), 2.27-2.57(m, 3H), 2.60-2.98(m, 7H), 3.33-3.56(m, 2H), 3.72-3.90(m, 10H), 3.94-4.07(m, 6H), 4.10-4.56(m, 15H), 5.10-5.27(m, 2H), 5.46-5.62(m, 1H), 6.00-6.42(m, 3H), 6.78-6.91(m, 4H), 7.18-7.40(m, 12H), 7.43-7.74(m, 5H), 7.82-8.12(m, 3H), 8.97-9.71(m, 3H). 31 P-NMR (162 MHz, CDCl 3):δ -1.86, -1.77, -1.72, -1.70, 1.60, -1.54, -1.50, -1.44. MALDI-TOF / MS: [M+Na] + 2439.2739.
[0114] Step 11-3: Synthesis of compound 32 According to the method of step 3-2, compound 32 (11.8 g, yield 95.9%) was obtained as an off-white solid from compound 31 (14.0 g, 5.79 mmol). 1 H-NMR (400 MHz, CDCl 3 ):δ 0.80-0.97(m, 9H), 1.17-1.54(m, 90H), 1.68-1.93(m, 12H), 2.33-2.96(m, 10H), 3.74-3.93(m, 6H), 3.94-4.08(m, 6H), 4.15-4.55(m, 15H), 5.13-5.31(m, 2H), 5.44-5.62(m, 1H), 5.98-6.28(m, 3H), 7.18-7.33(m, 2H), 7.38-7.67(m, 5H), 7.82-8.13(m, 3H), 9.24-10.00(m, 3H). 31 P-NMR (162 MHz, CDCl 3 ):δ -1.66, -1.60, -1.57, -1.55, -1.46, -1.41. MALDI-TOF / MS: [M+Na] + 2137.1420.
[0115] Step 11-4: Synthesis of compound 33 According to the method of step 3-3, compound 33 (5.20 g, yield 94.9%) was obtained as a yellow-brown white solid from compound 32 (4.00 g, 1.89 mmol) and compound 15 (2.27 g, 2.65 mmol). 1 H-NMR (400 MHz, CDCl 3):d 0.78-0.97(m, 9H), 1.16-1.56(m, 90H), 1,67-2.12(m, 12H), 2.32-2.96(m, 13H), 3.09-3.27(m, 1H), 3.34-3.52(m, 2H), 3.68-4.08(m, 16H), 4.15-4.56(m, 20H), 5.09-5.39(m, 2H), 5.43-5.60(m, 1H), 5.97-6.23(m, 3H), 6.44-6.59(m, 1H), 6.69-6.86(m, 4H), 7.11-7.66(m, 20H), 7.80-8.29(m, 6H), 8.59-8.74(m, 1H), 9.21-10.21(m, 4H). 31 P-NMR (162 MHz, CDCl 3 ):δ -1.78 - -1.26(m). MALDI-TOF / MS: [M+Na] + 2909.3931.
[0116] Example 12 (Selective deprotection of pseudo solid-phase protecting group from tetrameric oligonucleotide protected product): Synthesis of compound 34
[0117] [ka]
[0118] A solution of compound 33 (1.00 g, 0.346 mmol), methanol (333 mg, 10.4 mmol) and 4-pyrrolidinopyridine (5.13 mg, 34.6 μmol) in dichloromethane (6.9 g) was stirred at room temperature for 2 hours under a nitrogen atmosphere. The reaction solution was purified by column chromatography (spherical neutral silica gel, developing solvent: dichloromethane-methanol) to obtain compound 34 (493 mg, 78.3% yield) as a pale yellowish white solid. 1 H-NMR (400 MHz, CDCl 3 / CD 3OD 97 / 3 [v / v]):δ 1.75-1.97(m, 6H), 2.19-2.98(m, 13H), 3.09-3.24(m, 1H), 3.43-3.53(m, 2H), 3.68-3.86(m, 6H), 3.99-4.60(m, 17H), 5.07-5.42(m, 3H), 6.04-6.29(m, 3H), 6.47-6.59(m, 1H), 6.70-6.88(m, 4H), 7.12-7.41(m, 11H), 7.41-7.71(m, 7H), 7.88-8.14(m, 5H), 8.16-8.25(m, 1H), 8.63-8.73(m, 1H). 31 P-NMR (162 MHz, CDCl 3 ):δ -1.68 - -1.18(m). MALDI-TOF / MS: [M+Na] + 1840.4892.
[0119] Example 13 (Synthesis of sulfur-protected dimeric oligonucleotide): Synthesis of compound 35
[0120] [ka]
[0121] Under a nitrogen atmosphere, compound 8 (3.00 g, 2.14 mmol), compound 9 (2.57 g, 3.00 mmol) and molecular sieve 3A (0.60 g) were suspended in dichloromethane (29 g), BTT (480 mg, 3.00 mmol) was added at room temperature, and the mixture was stirred at room temperature for 3 hours. After cooling to 15 ° C, bis(phenylacetyl) disulfide (1.30 g, 4.30 mmol) was added, the mixture was heated to room temperature, and the mixture was stirred for 2.5 hours. The reaction solution was filtered, and the filtrate was added to acetonitrile (130 g), and the precipitated solid was filtered. The obtained solid was washed with acetonitrile and dried under reduced pressure at room temperature to obtain compound 35 (4.58 g, yield 97.9%) as a pale yellow solid. 1 H-NMR (400 MHz, CDCl 3):δ 0.79-0.98(m, 9H), 1.17-1.54(m, 90H), 1.68-1.87(m, 6H), 2.28-2.44(m, 1H), 2.58-3.00(m, 4H), 3.10-3.34(m, 1H), 3.37-3.57(m, 2H), 3.71-3.92(m, 10H), 3.93-4.08(m, 6H), 4.09-4.58(m, 10H), 5.37-5.57(m, 2H), 6.25-6.39(m, 1H), 6.43-6.60(m, 1H), 6.74-6.89(m, 4H), 7.15-7.34(m, 9H), 7.35-7.44(m, 2H), 7.44-7.70(m, 7H), 7.77-7.94(m, 2H), 7.98-8.15(m, 3H), 8.16-8.31(m, 1H), 8.60-9.30(m, 3H). 31 P-NMR (162 MHz, CDCl 3 ):δ 68.50, 68.65. MALDI-TOF / MS: [M+Na] + 2211.2168.
[0122] Example 14 (Selective deprotection of pseudo solid-phase protecting groups from sulfur-type dimeric oligonucleotide protectors): Synthesis of compound 36
[0123] [ka]
[0124] According to the method of Example 4, compound 36 (433 mg, yield 84.6%) was obtained as a slightly yellow solid from compound 35 (1.00 g, 0.457 mmol), ethylene glycol (425 mg, 6.85 mmol) and 4-pyrrolidinopyridine (10.1 mg, 68.1 mmol). 1 H-NMR (400 MHz, CDCl 3):δ 2.17-2.36(m, 1H), 2.62-2.87(m, 4H), 3.01-3.17(m, 1H), 3.36-3.57(m, 2H), 3.72-3.83(m, 6H), 4.08-4.58(m, 7H), 5.36-5.52(m, 1H), 6.17-6.30(m, 1H), 6.44-6.61(m, 1H), 6.74-6.87(m, 4H), 7.15-7.33(m, 7H), 7.34-7.67(m, 9H), 7.77-7.91(m, 2H), 7.95-8.07(m, 2H), 8.14-8.31(m, 2H), 8.60-8.68(m, 1H), 8.83-9.60(m, 2H). 31 P-NMR (162 MHz, CDCl 3 ):δ 68.58, 68.81. MALDI-TOF / MS: [M+Na] + 1142.3201.
[0125] Example 15 (Synthesis of an allyl-type dimeric protected oligonucleotide): Synthesis of compound 38
[0126] [ka]
[0127] Under a nitrogen atmosphere, 4,5-dicyanoimidazole (288 mg, 2.44 mmol) was added to a dichloromethane (10 g) solution of compound 37 (1.55 g, 2.45 mmol) and allyl tetraisopropyl phosphorodiamidite (770 mg, 2.67 mmol) at room temperature, and the mixture was stirred at room temperature for 1 hour (hereinafter also referred to as "reaction solution 37"). Compound 8 (2.00 g, 1.52 mmol) and molecular sieve 3A (0.40 g) were suspended in dichloromethane (6.0 g), reaction solution 37 and BTT (440 mg, 2.75 mmol) were added at room temperature, and the mixture was stirred at room temperature for 1.5 hours. 5.0 M TBHP / n-decane solution (762 μL, 3.80 mmol) was added at room temperature, and the mixture was stirred for 2 hours, after which the reaction solution was filtered, and the filtrate was added to acetonitrile (90 g) and the precipitated solid was filtered. The resulting solid was washed with acetonitrile and then dried under reduced pressure at room temperature to obtain compound 38 (2.71 g, yield 86.9%) as a slightly brownish white solid. 1 H-NMR (400 MHz, CDCl 3 ):δ 0.78-0.96(m, 9H), 1.15-1.54(m, 90H), 1.65-1.98(m, 9H), 2.26-2.63(m, 3H)2.87-3.06(m, 1H), 3.36-3.35(m, 2H), 3.71-3.91(m, 10H), 3.93-4.08(m, 6H), 4.12-4.67(m, 10H), 5.04-5.52(m, 3H), 5.80-6.00(m, 1H), 6.21-6.40(m, 2H), 6.78-6.94(m, 4H), 7.19-7.42(m, 13H), 7.46-7.70(m, 3H), 7.79-8.02(m, 2H), 8.05-8.27(m, 1H), 8.28-9.06(m, 2H). 31 P-NMR (162 MHz, CDCl 3 ):δ -0.91, -0.65. MALDI-TOF / MS: [M+Na] + 2069.2169.
[0128] Example 16 (Selective deprotection of pseudo solid-phase protecting groups from allyl-type dimeric oligonucleotide protected products): Synthesis of compound 39
[0129] [ka]
[0130] A solution of compound 38 (1.00 g, 0.488 mmol), methanol (469 mg, 14.6 mmol) and 4-pyrrolidinopyridine (10.9 mg, 73.5 μmol) in dichloromethane (9.7 g) was stirred at room temperature for 3 hours under a nitrogen atmosphere. The reaction solution was purified by column chromatography (spherical neutral silica gel, developing solvent: dichloromethane-acetone) to obtain compound 39 (393 mg, 82.2% yield) as a pale yellowish white solid. 1 H-NMR (400 MHz, CDCl 3 ):δ 1.80-1.95(m, 3H), 2.08-2.54(m, 3H), 2.91-3.13(m, 1H), 3.38-3.58(m, 2H), 3.66-3.86(m, 6H), 4.00-4.69(m, 7H), 4.98-5.44(m, 3H), 5.82-6.00(m, 1H), 6.16-6.35(m, 2H), 6.78-6.95(m, 4H), 7.18-7.47(m, 11H), 7.47-7.67(m, 3H), 7.84-8.01(m, 2H), 8.04-8.21(m, 1H), 8.52-9.49(m, 2H). 31 P-NMR (162 MHz, CDCl 3 ):δ -1.38, -0.03. MALDI-TOF / MS: [M+Na] + 1000.3106.
[0131] Example 17 (Synthesis of RNA-type dimeric protected oligonucleotide): Synthesis of compound 44
[0132] [ka]
[0133] Step 17-1: Synthesis of Compound 41 (RNA-type nucleoside protected compound) According to the method of step 3-1, compound 41 (6.72 g, yield 86.2%) was obtained as a slightly brownish white solid from compound 5 (5.00 g, 4.44 mmol) and compound 40 (4.28 g, 6.22 mmol). 1 H-NMR (400 MHz, CDCl 3 ):δ 0.80-0.95(m, 9H), 1.16-1.55(m, 90H), 1.66-1.89(m, 6H), 3.36(s, 3H), 3.40-3.50(m, 1H), 3.57-3.67(m, 1H), 3.75-3.93(m, 10H), 3.95-4.08(m, 6H), 4.39-4.54(m, 5H), 4.96-5.08(m, 1H), 5.58-5.66(m, 1H), 6.09-6.17(m, 1H), 6.78-6.87(m, 4H), 7.17-7.37(m, 10H), 7.39-7.47(m, 2H), 7.48-7.65(m, 3H), 7.98-8.08(m, 1H), 8.19(s, 1H), 8.69(brs, 1H), 9.02(brs, 1H). 13 C-NMR (100 MHz, CDCl 3):δ 14.1, 22.7, 26.1, 26.1, 29.3, 29.4, 29.4, 29.6, 29.7, 29.7, 30.4, 32.0, 55.2, 59.6, 55.2, 59.6, 62.8, 63.8, 66.2, 68.3, 69.2, 69.4, 73.5, 73.9, 80.9, 81.7, 87.1, 108.1, 113.3, 123.6, 124.4, 127.1, 127.9, 128.0, 128.1, 130.0, 130.0, 132.9, 133.6, 135.3, 135.4, 142.1, 142.6, 144.3, 149.6, 151.9, 152.8, 152.8, 156.4, 156.9, 158.7, 164.5, 166.4.
[0134] Step 17-2: Synthesis of compound 42 According to the method of step 3-2, compound 42 (5.05 g, yield 98.4%) was obtained as a slightly brownish white solid from compound 41 (6.20 g, 3.53 mmol). 1 H-NMR (400 MHz, CDCl 3 ):δ 0.81-0.95(m, 9H), 1.16-1.54(m, 90H), 1.69-1.86(m, 6H), 3.27(s, 3H), 3.77-3.92(m, 5H), 3.95-4.08(m, 7H), 4.41-4.57(m, 5H), 4.81-4.92(m, 1H), 5.74-5.85(m, 1H), 5.89-5.98(m, 1H), 6.30(brs, 1H), 7.27(s, 1H), 7.50-7.68(m, 3H), 7.99-8.08(m, 2H), 8.11(s, 1H), 8.81(brs, 1H), 9.12(brs, 1H). 13 C-NMR (100 MHz, CDCl 3):δ 14.1, 22.7, 26.1, 26.1, 29.4, 29.6, 29.7, 29.7, 30.3, 31.9, 59.8, 62.9, 63.8, 66.2, 68.3, 69.3, 69.4, 73.5, 75.0, 81.1, 85.4, 89.4, 108.2, 124.4, 124.7, 127.9, 129.0, 133.1, 133.3, 142.6, 143.4, 150.4, 150.5, 152.2, 152.9, 156.4, 157.0, 164.4, 166.4.
[0135] Step 17-3: Synthesis of compound 44 According to the method of step 3-3, compound 44 (6.51 g, yield 94.5%) was obtained as a slightly brownish white solid from compound 42 (4.50 g, 3.09 mmol) and compound 43 (3.73 g, 4.33 mmol). 1 H-NMR (400 MHz, CDCl 3 ):δ 0.04-0.18(m, 6H), 0.80-0.97(m, 18H), 1.17-1.54(m, 90H), 1.68-1.87(m, 6H), 2.47-2.74(m, 2H), 3.32-3.70(m, 5H), 3.73-3.92(m, 10H), 3.94-4.59(m, 16H), 4.85-5.06(m, 2H), 5.18-5.29(m, 1H), 5.59-5.71(m, 1H), 5.92-6.14(m, 2H), 6.78-6.90(m, 4H), 7.16-7.38(m, 12H), 7.45-7.65(m, 3H), 7.78-7.88(m, 1H), 7.98-8.10(m, 1H), 8.15-8.26(m, 1H), 8.76-8.86(m, 1H), 8.87-9.12(m, 1H), 9.24-9.40(m, 1H). 31 P-NMR (162 MHz, CDCl 3 ):δ -1.32, -1.13. MALDI-TOF / MS: [M+Na] + 2252.2939.
[0136] Example 18 (Selective deprotection of pseudo solid-phase protecting groups from RNA-type dimeric oligonucleotide protectors): Synthesis of compound 45
[0137] [ka]
[0138] According to the method of Example 16, compound 45 (432 mg, yield 82.9%) was obtained as a white solid from compound 44 (1.00 g, 0.448 mmol), methanol (431 mg, 13.5 mmol) and 4-pyrrolidinopyridine (6.64 mg, 44.8 μmol). 1 H-NMR (400 MHz, CDCl 3 ):δ 0.03-0.20(m, 6H), 0.75-0.96(m, 9H), 2.48-2.78(m, 2H), 3.41-3.68(m, 5H), 3.72-3.87(m, 6H), 3.95-4.60(m, 9H), 4.84-4.99(m, 1H), 5.22-5.31(m, 1H), 5.98-6.08(m, 1H), 6.10-6.22(m, 1H), 6.77-6.92(m, 4H), 7.17-7.41(m, 10H), 7.45-7.65(m, 3H), 7.78-7.89(m, 1H), 7.98-8.11(m, 1H), 8.17-8.31(m, 1H), 8.75-8.88(m, 1H), 9.33-9.84(m, 2H). 31 P-NMR (162 MHz, CDCl 3 ):δ -0.91, -0.80. MALDI-TOF / MS: [M+Na] + 1183.3982.
[0139] Example 19 (Synthesis of pseudo solid-phase protecting group (variant 1)): Synthesis of compound 47
[0140] [ka]
[0141] Step 19-1: Synthesis of compound 46 Compound 46 (10.2 g, 97.0% yield) was obtained as a slightly yellowish white solid from compound 3 (10.0 g, 10.8 mmol) and ethylene glycol (10.0 g, 161 mmol) according to the method of step 2-1, except that diethylene glycol was changed to ethylene glycol. 1 H-NMR (400 MHz, CDCl 3 ):δ 0.80-0.95(m, 9H), 1.16-1.54(m, 90H), 1.67-1.88(m, 6H), 3.90-4.10(m, 8H), 4.41-4.51(m, 2H), 7.26(s, 2H). 13 C-NMR (100 MHz, CDCl 3 ):δ 14.1, 22.7, 26.1, 26.1, 29.4, 29.4, 29.5, 29.6, 29.7, 29.7, 29.8, 30.4, 32.0, 61.7, 66.8, 69.4, 69.5, 73.6, 108.6, 124.4, 143.1, 153.0, 167.0.
[0142] Step 19-2: Synthesis of compound 47 According to the method of step 2-2, compound 47 (6.59 g, yield 84.8%) was obtained as a slightly yellowish white solid from oxalyl chloride (2.74 g, 21.6 mmol) and compound 46 (7.00 g, 7.20 mmol). 1 H-NMR (400 MHz, CDCl 3 , 50 ℃):δ 0.83-0.93(m, 9H), 1.16-1.50(m, 90H), 1.61-1.79(m, 6H), 3.80-4.02(m, 6H), 4.22-4.56(m, 4H), 7.16(brs, 2H). 13 C-NMR (100 MHz, CDCl 3, 50℃):δ 14.1, 22.7, 26.2, 26.3, 29.4, 29.6, 29.7, 29.7, 29.8, 29.8, 29.8, 29.9, 29.9, 29.9, 30.5, 32.0, 62.2, 63.4, 69.4, 73.5, 108.5, 124.0, 143.0, 152.9, 162.1, 165.2, 166.5.
[0143] Example 20 (Synthesis of A-terminal protected dimeric oligonucleotide): Synthesis of compound 50
[0144] [ka]
[0145] Step 20-1: Synthesis of compound 48 (protected nucleoside) According to the method of step 5-1, compound 48 (11.7 g, yield 93.8%) was obtained as a slightly brownish white solid from compound 47 (8.00 g, 7.40 mmol) and compound 18 (5.84 g, 8.88 mmol). 1 H-NMR (400 MHz, CDCl 3 ):δ 0.81-0.95(m, 9H), 1.16-1.53(m, 90H), 1.65-1.87(m, 6H), 2.68-2.80(m, 1H), 3.13-3.27(m, 1H), 3.41-3.56(m, 2H), 3.72-3.82(m, 6H), 3.94-4.06(m, 6H), 4.35-4.42(m, 1H), 4.55-4.72(m, 4H), 5.64-5.74(m, 1H), 6.45-6.56(m, 1H), 6.73-6.86(m, 4H), 7.16-7.33(m, 9H), 7.35-7.42(m, 2H), 7.50-7.66(m, 3H), 7.98-8.08(m, 2H), 8.18(s, 1H), 8.70(brs, 1H), 8.94(brs, 1H). 13 C-NMR (100 MHz, CDCl 3):δ 14.1, 22.7, 26.1, 26.1, 29.3, 29.4, 29.4, 29.6, 29.7, 29.7, 30.4, 31.9, 37.3, 55.2, 62.0, 63.3, 64.8, 69.2, 73.5, 78.2, 84.0, 84.7, 86.9, 108.2, 113.2, 123.4, 123.9, 127.0, 127.8, 128.0, 128.9, 130.0, 130.0, 132.8, 133.6, 135.3, 135.4, 141.4, 142.8, 144.3, 149.6, 151.5, 152.7, 152.9, 156.7, 157.0, 158.6, 158.6, 164.5, 166.1.
[0146] Step 20-2: Synthesis of compound 49 According to the method of step 3-2, compound 49 (7.95 g, yield 97.0%) was obtained as a slightly brownish white solid from compound 48 (10.0 g, 5.94 mmol). 1 H-NMR (400 MHz, CDCl 3 ):δ 0.81-0.94(m, 9H), 1.15-1.53(m, 90H), 1.68-1.85(m, 6H), 2.48-2.62(m, 1H), 3.21-3.36(m, 1H), 3.87-4.09(m, 8H), 4.32-4.40(m, 1H), 4.53-4.74(m, 4H), 5.70-5.79(m, 1H), 6.28-6.40(m, 1H), 7.26(brs, 1H), 7.51-7.59(m, 2H), 7.60-7.67(m, 1H), 8.00-8.06(m, 2H), 8.10(s, 1H), 8.80(s, 1H), 9.05(brs, 1H). 13 C-NMR (100 MHz, CDCl 3):δ 14.1, 22.7, 26.1, 26.1, 29.3, 29.4, 29.4, 29.6, 29.7, 29.7, 30.3, 31.9, 37.5, 61.9, 63.2, 64.7, 69.3, 73.6, 79.3, 86.9, 87.6, 108.2, 123.9, 124.6, 127.9, 129.0, 133.0, 133.4, 142.6, 142.8, 150.5, 150.5, 152.2, 152.9, 156.7, 157.1, 164.5, 166.0.
[0147] Step 20-3: Synthesis of compound 50 According to the method of step 3-3, compound 50 (10.7 g, yield 94.9%) was obtained as a slightly brownish white solid from compound 49 (7.30 g, 5.29 mmol) and compound 21 (6.21 g, 7.39 mmol). 1 H-NMR (400 MHz, CDCl 3 ):δ 0.81-0.94(m, 9H), 0.97-1.54(m, 97H), 1.67-1.86(m, 6H), 2.33-2.48(m, 1H), 2.52-2.97(m, 6H), 3.19-3.52(m, 3H), 3.66-3.81(m, 6H), 3.91-4.75(m, 16H), 5.19-5.38(m, 1H), 5.67-5.84(m, 1H), 5.99-6.12(m, 1H), 6.40-6.55(m, 1H), 6.68-6.84(m, 4H), 7.12-7.63(m, 14H), 7.66-7.75(m, 1H), 7.84-8.03(m, 2H), 8.22-8.33(m, 1H), 8.74-8.86(m, 1H), 9.03-9.29(m, 1H), 9.41-9.80(m, 1H), 11.71-12.27(m, 1H). 31 P-NMR (162 MHz, CDCl 3 ):δ -1.50, -1.19. MALDI-TOF / MS: [M+Na] + 2157.2363.
[0148] Example 21 (Selective deprotection of pseudo solid-phase protecting group from A-terminal dimer oligonucleotide protector): Synthesis of compound 23
[0149] [ka]
[0150] According to the method of Example 4, compound 23 (485 mg, yield 93.3%) was obtained as a white solid from compound 50 (1.00 g, 0.468 mmol), ethylene glycol (436 mg, 7.02 mmol) and 4-pyrrolidinopyridine (6.94 mg, 46.8 μmol). 1 H-NMR (400 MHz, CDCl 3 ):δ 1.02-1.19(m, 6H), 2.38-3.15(m, 6H), 3.24-3.34(m, 2H), 3.68-3.80(m, 6H), 3.96-4.52(m, 6H), 4.87-5.06(m, 1H), 5.17-5.47(m, 1H), 6.01-6.13(m, 1H), 6.41-6.55(m, 1H), 6.70-6.85(m, 4H), 7.12-7.41(m, 9H),7.41-7.55(m, 2H), 7.55-7.71(m, 2H), 7.85-8.06(m, 2H), 8.20-8.44(m, 1H), 8.72-8.87(m, 1H), 9.11-9.32(m, 1H), 9.50-10.14(m, 1H), 11.87-12.09(m, 1H). 31 P-NMR (162 MHz, CDCl 3 ):δ -1.57, -0.94. MALDI-TOF / MS: [M+Na] + 1132.3650.
[0151] Example 22 (Synthesis of pseudo solid-phase protecting group (variant 2)): Synthesis of compound 53
[0152] [ka]
[0153] Step 22-1: Synthesis of compound 52 Under a nitrogen atmosphere, a mixture of 1-octadecanol (2.46 g, 9.09 mmol), potassium hydroxide (532 mg, 9.48 mmol), toluene (7.6 g) and water (1.0 g) was stirred under heating and reflux for 2 hours, and water was removed using a Dean-Stark trap. After that, n-tetrabutylammonium bromide (139 mg, 0.431 mmol), compound 51 (0.400 g, 4.32 mmol) and THF (3.8 g) were added and stirred at 40 ° C for 16 hours. A 10% aqueous ammonium chloride solution was added to the reaction solution, and the organic layer was washed with saturated saline, and anhydrous sodium sulfate was added to the obtained organic layer, which was then filtered. The filtrate was concentrated under reduced pressure, and 1-octadecanol (1.05 g, 3.88 mmol) and dichloromethane (90 g) were added to the resulting residue under a nitrogen atmosphere. After cooling to 10°C, boron trifluoride diethyl ether complex (123 mg, 0.867 mmol) was added. After stirring at 10°C for 3 hours, the mixture was washed with a 5% aqueous sodium bicarbonate solution, and the aqueous layer was re-extracted with dichloromethane. The organic layers were combined and washed with saturated saline, and anhydrous sodium sulfate was added to the resulting organic layer, followed by filtration. The filtrate was concentrated under reduced pressure, and the resulting solid was washed with isopropyl alcohol and dried under reduced pressure at room temperature to obtain compound 52 (1.29 g, yield 50.0%) as a white solid. 1 H-NMR (400 MHz, CDCl 3 ):δ 0.81-0.95(m, 6H), 1.16-1.39(m, 60H), 1.49-1.67(m, 4H), 2.44-2.51(m, 1H), 3.37-3.54(m, 8H), 3.89-4.00(m, 1H). 13 C-NMR (100 MHz, CDCl 3 ):δ 14.1, 22.7, 26.1, 29.4, 29.5, 29.6, 29.7, 29.7, 31.9, 69.5, 71.7, 71.8.
[0154] Step 22-2: Synthesis of compound 53 According to the method of step 2-2, compound 53 (1.91 g, yield 90.1%) was obtained as a slightly yellowish white solid from oxalyl chloride (1.15 g, 9.06 mmol) and compound 52 (1.80 g, 3.01 mmol). 1 H-NMR (400 MHz, CDCl 3 , 50 ℃):δ 0.80-1.00(m, 6H), 1.13-1.39(m, 56H), 1.45-1.65(m, 4H), 1.73-2.01(m, 4H), 3.28-3.66(m, 8H), 4.85-5.05(m, 1H). 13 C-NMR (100 MHz, CDCl 3 ):δ 14.1, 22.7, 25.9, 26.1, 29.3, 29.4, 29.4, 29.6, 29.6, 29.7, 29.7, 29.7, 31.9, 68.6, 72.0, 74.4, 157.1, 157.6.
[0155] Example 23 (Synthesis of a T-terminal protected oligonucleotide dimer): Synthesis of compound 56
[0156] [ka]
[0157] Step 23-1: Synthesis of compound 54 (protected nucleoside) According to the method of step 3-1, compound 54 (2.60 g, yield 76.9%) was obtained as a white solid from compound 53 (2.00 g, 2.83 mmol) and compound 6 (2.32 g, 4.26 mmol). 1 H-NMR (400 MHz, CDCl 3):δ 0.80-0.95(m, 6H), 1.16-1.45(m, 63H), 1.49-1.60(m, 4H), 2.43-2.68(m, 2H), 3.35-3.59(m, 6H), 3.64(d, 4H, J= 5.2Hz), 3.80(s, 6H), 4.20-4.28(m, 1H), 5.27(sext, 1H, J= 5.2 Hz), 5.51-5.62(m, 1H), 6.43-6.53(m, 1H), 6.79-6.92(m, 4H), 7.20-7.42(m, 7H), 7.59-7.66(m, 1H), 8.24(s, 1H). 13 C-NMR (100 MHz, CDCl 3 ):δ 11.6, 14.1, 22.7, 26.0, 29.4, 29.5, 29.6, 29.7, 29.7, 31.9, 37.7, 55.3, 63.5, 68.7, 71.8, 75.2, 78.1, 83.6, 84.3, 87.3, 111.7, 113.4, 127.3, 128.1, 128.1, 130.0, 130.1, 135.0, 135.1, 135.2, 144.1, 150.1, 156.6, 157.2, 158.8, 158.8, 163.3.
[0158] Step 23-2: Synthesis of compound 55 According to the method of step 3-2, compound 55 (1.76 g, yield 98.3%) was obtained as a white solid from compound 54 (2.40 g, 2.01 mmol). 1 H-NMR (400 MHz, CDCl 3):δ 0.80-0.95(m, 6H), 1.17-1.38(m, 60H), 1.48-1.61(m, 4H), 1.94(d, 3H, J= 1.2 Hz), 2.43-2.70(m, 2H), 3.37-3.53(m, 4H), 3.64 (d, 4H, J= 5.2 Hz), 3.90-4.01(m, 2H), 4.19-4.25(m, 1H), 5.29(sext, 1H, J= 5.2 Hz), 5.48-5.56(m, 1H), 6.16-6.23(m, 1H), 7.43(d, 1H, J= 1.2 Hz), 8.21(brs, 1H). 13 C-NMR (100 MHz, CDCl 3 ):δ 12.6, 14.1, 22.7, 26.0, 29.4, 29.5, 29.5, 29.6, 29.7, 29.7, 31.9, 36.7, 62.6, 69.7, 71.8, 75.2, 76.7, 77.7, 84.7, 87.2, 111.5, 136.7, 150.1, 156.7, 157.3, 163.2.
[0159] Step 23-3: Synthesis of compound 56 According to the method of step 3-3, compound 56 (2.00 g, yield 83.7%) was obtained as a white solid from compound 55 (1.30 g, 1.46 mmol) and compound 9 (1.70 g, 2.04 mmol). 1 H-NMR (400 MHz, CDCl 3):δ0.83-0.94(m, 6H), 1.18-1.37(m, 60H), 1.48-1.60(m, 4H), 1.86-1.98(m, 3H), 2.31-3.05(m, 6H), 3.35-3.56(m,6H), 3.59-3.70(m, 4H), 3.73-3.86(m, 6H), 4.09-4.46(m, 6H), 5.08-5.21(m, 1H), 5.23-5.34(m, 1H), 5.36-5.52(m, 1H), 6.20-6.36(m, 2H), 6.79-6.93(m, 4H), 7.20-7.40(m, 11H), 7.47-7.66(m, 3H), 7.82-7.96(m,2H), 8.06-8.88(m,3H). 31 P-NMR (162 MHz, CDCl 3 ):δ -1.61, -1.59. MALDI-TOF / MS: [M+Na] + 1663.8936.
[0160] Example 24 (Selective deprotection of pseudo solid-phase protecting group from T-terminal dimer protected oligonucleotide): Synthesis of compound 11
[0161] [ka]
[0162] According to the method of Example 4, compound 11 (485 mg, yield 80.4%) was obtained as a white solid from compound 56 (1.00 g, 0.609 mmol), ethylene glycol (567 mg, 9.13 mmol) and 4-pyrrolidinopyridine (13.5 mg, 91.1 μmol). 1 H-NMR (400 MHz, CDCl 3):δ 1.86-1.90(m, 3H), 2.17-2.50(m, 3H), 2.67-2.80(m, 2H), 2.95-3.09(m, 1H), 3.40-3.54(m, 2H), 3.74-3.84(m, 6H), 4.04-4.45(m, 6H), 4.46-4.61(m, 1H), 5.03-5.22(m, 1H), 6.16-6.30(m, 2H), 6.80-6.92(m, 4H), 7.20-7.44(m, 11H), 7.45-7.54(m, 2H), 7.54-7.64(m, 1H), 7.89-8.02(m, 2H), 8.05-8.16(m, 1H), 9.06-9.84(m, 2H). 31 P-NMR (162 MHz, CDCl 3 ):δ -1.94, -1.13. MALDI-TOF / MS: [M+Na] + 1013.3062.
[0163] Example 25 (Synthesis of pseudo solid-phase protecting group (variant 3)): Synthesis of compound 58
[0164] [ka]
[0165] Step 25-1: Synthesis of compound 57 Under a nitrogen atmosphere, compound 3 (13.0 g, 14.0 mmol), 2-(methylamino)ethanol (3.16 g, 42.1 mmol) and N-methylimidazole (3.46 g, 42.1 mmol) were suspended in THF (120 g), and HBTU (7.97 g, 21.0 mmol) was added at room temperature and stirred at room temperature for 3 hours. The reaction solution was added to acetonitrile (330 g) and the precipitated solid was filtered. The obtained solid was washed with acetonitrile and dried under reduced pressure at room temperature to obtain compound 57 (13.0 g, yield 93.9%) as a pale yellowish white solid. 1 H-NMR (400 MHz, CDCl 3, 50 ℃):δ 0.82-0.94(m, 9H), 1.15-1.53(m, 90H), 1.68-1.84(m, 6H), 3.06(brs, 3H), 3.56-3.72(m, 2H), 3.77-3.91(m, 2H), 3.94-4.02(m, 6H), 6.63(s, 2H). 13 C-NMR (100 MHz, CDCl 3 , 50℃):δ 14.1, 22.7, 26.1, 29.4, 29.5, 29.6, 29.7, 29.7, 29.8, 30.4, 32.0, 38.6, 51.7, 61.2, 69.5, 73.5, 106.3, 110.8, 118.5, 124.3, 130.6, 139.9, 153.2, 173.3.
[0166] Step 25-2: Synthesis of compound 58 According to the method of step 2-2, compound 58 (13.7 g, yield 98.6%) was obtained as a white solid from oxalyl chloride (4.84 g, 38.1 mmol) and compound 57 (12.5 g, 12.7 mmol). 1 H-NMR (400 MHz, CDCl 3 , 50 ℃):δ 0.80-0.95(m, 9H), 1.15-1.52(m, 90H), 1.65-1.82(m, 6H), 2.93(brs, 3H), 3.57-3.75(m, 2H), 3.83-3.99(m, 6H), 4.15-4.33(m, 2H), 6.55(brs, 2H). 13 C-NMR (100 MHz, CDCl 3 , 50℃):δ 14.1, 22.7, 26.3, 26.4, 29.4, 29.6, 29.7, 29.7, 29.8, 29.8, 29.8, 29.8, 29.9, 29.9, 30.5, 32.0, 38.1, 46.4, 61.7, 69.5, 73.5, 105.9, 130.8, 139.6, 153.2, 162.3, 165.5, 171.9.
[0167] Example 26 (Synthesis of a T-terminal protected oligonucleotide dimer): Synthesis of compound 61
[0168] [ka]
[0169] Step 26-1: Synthesis of compound 59 (protected nucleoside) According to the method of step 3-1, compound 59 (12.4 g, yield 85.7%) was obtained as a slightly brownish white solid from compound 58 (10.0 g, 9.13 mmol) and compound 6 (6.96 g, 12.8 mmol). 1 H-NMR (400 MHz, CDCl 3 , 50 ℃):δ 0.81-0.95(m, 9H), 1.15-1.53(m, 93H), 1.68-1.83(m, 6H), 2.41-2.66(m, 2H), 3.04-3.13(m, 3H), 3.42-3.58(m, 2H), 3.71-3.89(m, 8H), 3.89-4.05(m, 6H), 4.18-4.25(m, 1H), 4.40-4.64(m, 2H), 5.51-5.58(m, 1H), 6.38-6.47(m, 1H), 6.56-6.62(m, 2H), 6.79-6.88(m, 4H), 7.19-7.34(m, 7H), 7.34-7.42(m, 2H), 7.53-7.59(m, 1H), 8.38(brs, 1H). 13 C-NMR (100 MHz, CDCl 3, 50℃):δ 11.7, 14.1, 22.7, 26.2, 29.4, 29.5, 29.7, 29.7, 29.7, 29.8, 30.4, 32.0, 37.8, 55.3, 63.6, 64.9, 69.5, 73.5, 78.2, 83.6, 84.5, 87.5, 106.0, 111.8, 113.5, 127.3, 128.1, 128.2, 130.1, 130.1, 130.6, 135.1, 135.2, 135.2, 139.8, 144.2, 150.2, 153.3, 156.9, 159.0, 159.0, 163.3, 172.0.
[0170] Step 26-2: Synthesis of compound 60 According to the method of step 3-2, compound 60 (8.70 g, yield 88.6%) was obtained as a slightly brownish white solid from compound 59 (11.0 g, 6.95 mmol). 1 H-NMR (400 MHz, CDCl 3 , 50 ℃):δ 0.84-0.92(m, 9H), 1.16-1.51(m, 90H), 1.68-1.84(m, 6H), 1.88-1.93(m, 3H), 2.39-2.47(m, 1H), 2.59-2.69(m, 1H), 3.06-3.12(m, 3H), 3.75-4.02(m, 10H), 4.15-4.21(m, 1H), 4.45-4.61(m, 2H), 5.50-5.55(m, 1H), 6.09-6.15(m, 1H), 6.57-6.62(m, 2H), 7.38-7.43(m, 1H), 8.57(brs, 1H). 13 C-NMR (100 MHz, CDCl 3, 50 ℃): δ 12.4, 14.1, 22.7, 26.2, 29.4, 29.5, 29.7, 29.7, 29.8, 29.8, 30.4, 32.0, 36.7, 62.5, 64.4, 69.5, 73.6, 84.8, 87.5, 106.0, 111.5, 130.6, 137.0, 139.8, 150.3, 153.3, 156.9, 157.0, 163.4, 172.1.
[0171] Project 26-3: Synthesis of Compound 61 The method of Process 3-3 was to obtain compound 60 (2.80 g, 2.19 mmol), compound 9 (2.48 g, 2.97 mmol), and compound 61 (4.11 g, yield 93.0%) as a slightly brownish white solid. 1 H-NMR (400 MHz, CDCl 3 , 50 ℃): δ 0.81-0.95(m, 9H), 1.15-1.53(m, 90H), 1.68-2.00(m, 9H), 2.27-2.80(m, 4H), 2.90-3.02(m, 1H), 3.02-3.15(m, 3H), 3.42-3.54(m, 2H), 3.67-4.72(m, 22H), 5.09-5.19(m, 1H), 5.42-5.53(m, 1H), 6.16-6.29(m, 2H), 6.57-6.63(m, 2H), 6.82-6.89(m, 4H), 7.21-7.39(m, 11H), 7.44-7.52(m, 2H), 7.55-7.62(m, 1H), 7.89-7.96(m, 2H), 8.05-8.12(m, 1H), 8.69-9.11(m, 2H). 31 P-NMR (162 MHz, CDCl 3 , 50 ℃):δ -1.70, -1.59. MALDI-TOF / MS:[M+Na] + 2051.2039.
[0172] Example 27 (Selective deprotection of pseudo solid-phase protecting group from T-terminal dimer protected oligonucleotide): Synthesis of compound 11
[0173] [ka]
[0174] According to the method of Example 4, compound 11 (430 mg, yield 88.1%) was obtained as a white solid from compound 61 (1.00 g, 0.493 mmol), ethylene glycol (428 mg, 6.90 mmol) and 4-pyrrolidinopyridine (17.5 mg, 0.118 mmol). 1 H-NMR (400 MHz, CDCl 3 ):δ 1.86-1.90(m, 3H), 2.17-2.50(m, 3H), 2.67-2.80(m, 2H), 2.95-3.09(m, 1H), 3.40-3.54(m, 2H), 3.74-3.84(m, 6H), 4.04-4.45(m, 6H), 4.46-4.61(m, 1H), 5.03-5.22(m, 1H), 6.16-6.30(m, 2H), 6.80-6.92(m, 4H), 7.20-7.44(m, 11H), 7.45-7.54(m, 2H), 7.54-7.64(m, 1H), 7.89-8.02(m, 2H), 8.05-8.16(m, 1H), 9.06-9.84(m, 2H). 31 P-NMR (162 MHz, CDCl 3 ):δ -1.94, -1.13. MALDI-TOF / MS: [M+Na] + 1013.3062.
[0175] Example 28 (Comparison of selective deprotection rates): Formation of compound 6
[0176] [ka]
[0177] The reaction rates (production rate of compound 6) of compound 59, compound 62 and compound 63 were compared under the selective deprotection conditions shown below. The results are shown in the table below. Compound 62 was synthesized in the same manner as in the synthesis of compound 32 in step 2 in Example 17 described in Patent Document 3, except that compound 1 described in Patent Document 3 was changed to compound 6. Compound 63 was synthesized in the same manner as in Examples 1-1, 1-2 and 2-1 described in Patent Document 5. The production rate of compound 6 was calculated by the following formula (1) using the peak area values of each compound measured based on the ultra-high performance liquid chromatography (UHPLC) conditions shown below.
[0178] [number] Production rate of compound 6=(peak area value of compound 6) / [(peak area value of compound 59, compound 62, or compound 63)+(peak area value of compound 6)]×100 (1).
[0179] Selective deprotection conditions Under a nitrogen atmosphere, a solution of each compound (compound 59, compound 62, or compound 63) (30.0 μmol), ethylene glycol (450 μmol), and 4-pyrrolidinopyridine (15.0 μmol) in THF (0.45 mL) was stirred at a reaction temperature of 25° C. for a predetermined time.
[0180] <UHPLC conditions> Column: Acquity UPLC BEH C18 (φ2.1×100 mm, 1.7 μm) ·Flow rate: 0.25 mL / min Mobile phase A: 100 mmol / L triethylamine acetate buffer Mobile phase B: THF / acetonitrile = 60 / 40 Mobile phase A / B = 60 / 40 → (12 min) → 0 / 100 (8 min) → (0.1 min) → 60 / 40 (10.9 min) Column temperature: 30 °C Detection method: UV (λ=260 nm) ·Retention time: Compound 59 (RT 15.3 min), Compound 62 (RT 15.3 min), Compound 63 (RT 15.6 min), Compound 6 (RT 4.1 min).
[0181] [Table 2]
[0182] From these results, it was confirmed that the pseudo solid-phase protecting group having an oxalate ester structure (compound 59) was deprotected more quickly than the conventional pseudo solid-phase protecting groups (compounds 62 and 63) under selective deprotection conditions combining a nucleophile and a base.
[0183] Example 29 (Comparison of overall deprotection rates): Formation of compound 6
[0184] [ka]
[0185] The reaction rates (production rate of compound 6) of compound 59 (see Example 28), compound 63 (see Example 28), and compound 64 were compared under the general overall deprotection conditions for oligonucleotide synthesis shown below. The results are shown in the table below. Compound 64 was synthesized in the same manner as in Example 1 described in Patent Document 2. The production rate of compound 6 was determined in the same manner as in Example 28.
[0186] 《Total deprotection conditions》 Under a nitrogen atmosphere, each compound (compound 59, compound 63, or compound 64) (50.0 μmol), 28% aqueous ammonia (2.0 mL), ethanol (0.5 mL), and THF (0.5 mL) were stirred at a reaction temperature of 35° C. for a predetermined time.
[0187] [Table 3]
[0188] From this result, it was confirmed that the pseudo solid-phase protecting group having an oxalate ester structure (compound 59) was deprotected more quickly than the conventional pseudo solid-phase protecting groups (compounds 63 and 64) under all general deprotection conditions for oligonucleotide synthesis. Thus, it was confirmed that the pseudo solid-phase protecting group having an oxalate ester structure (compound 59) can be used for oligonucleotide synthesis because deprotection proceeded under these conditions.
[0189] Example 30 (Study of selective deprotection reaction (conditions)): Formation of compound 11
[0190] [ka]
[0191] We investigated the conditions for selectively deprotecting only the pseudo solid-phase protecting group attached to the 3' end from an oligonucleotide protected with a pseudo solid-phase protecting group having an oxalate structure. In this example, we used compound 10 and investigated the types of base and nucleophile, as well as their equivalents.
[0192] (Example 30-1) Examination of base species Compound 10 was reacted under the selective deprotection conditions shown below, and the production rate of compound 11 for each base type was compared. The results are shown in the table below. The production rate of compound 11 was determined by the same method as in Example 28. The retention times are compound 10 (RT 15.1 min) and compound 11 (RT 4.3 min). In addition, the calculation was performed by changing compound 6 to compound 11, and compound 59, compound 62, or compound 63 to compound 10 in the above formula (1).
[0193] Selective deprotection conditions Under a nitrogen atmosphere, a solution of compound 10 (24.3 μmol), each base shown in the table below (72.9 μmol) and 2-cyanoethanol (725 μmol) in THF (0.4 mL) was stirred at a reaction temperature of 25° C. for a predetermined time.
[0194] [Table 4]
[0195] These results confirmed that the reaction proceeds with various bases in the selective deprotection of only the pseudo solid-phase protecting group attached to the 3' position from an oligonucleotide protected with a pseudo solid-phase protecting group having an oxalate ester structure.
[0196] (Example 30-2) Examination of base equivalent Compound 10 was reacted under the selective deprotection conditions shown below, and the production rate of compound 11 relative to the base equivalent was compared. The results are shown in the table below. The production rate of compound 11 was determined by the same method as in Example 28.
[0197] Selective deprotection conditions Under a nitrogen atmosphere, a solution of compound 10 (24.3 μmol), triethylamine (base equivalent shown in the table below) as a base, and 2-cyanoethanol (725 μmol) in THF (0.4 mL) was stirred at a reaction temperature of 25° C. for a predetermined time.
[0198] [Table 5]
[0199] From these results, it was confirmed that in the reaction for selectively deprotecting only the pseudo solid-phase protecting group attached to the 3' position from a protected oligonucleotide protected with a pseudo solid-phase protecting group having an oxalate ester structure, the reaction proceeds under the condition that the base is used in an amount of 1 equivalent or less (e.g., 0.5 equivalents) or 1 equivalent or more (e.g., 1 to 3 equivalents) relative to the reaction substrate, compound 10 (protected oligonucleotide).
[0200] (Example 30-3) Examination of nucleophiles A solution of compound 10 (50.0 mg, 24.3 μmol), 4-dimethylaminopyridine (1.48 mg, 12.1 μmol) and each nucleophile shown in the table below in THF (330 mg) was stirred at 25° C., and the production rate of compound 11 relative to the type of nucleophile was compared. The results are shown in the table below. The production rate of compound 11 was determined by the same method as in Example 28.
[0201] [Table 6]
[0202] These results confirmed that the reaction proceeds with various nucleophiles in the selective deprotection of only the pseudo solid-phase protecting group attached to the 3' position from an oligonucleotide protected with a pseudo solid-phase protecting group having an oxalate ester structure.
[0203] (Example 30-4) Study of aliphatic amino alcohols Compound 10 was reacted under the selective deprotection conditions shown below, and the production rate of compound 11 for each aliphatic amino alcohol was compared. The results are shown in the table below. The production rate of compound 11 was determined by the same method as in Example 28.
[0204] Selective deprotection conditions Under a nitrogen atmosphere, a THF (0.4 mL) solution containing compound 10 (24.3 μmol) and each aliphatic amino alcohol (26.7 μmol) shown in the following table was stirred at a reaction temperature of 25° C. for a predetermined time.
[0205] [Table 7]
[0206] These results confirmed that the reaction proceeds with various aliphatic amino alcohols in the selective deprotection of only the pseudo solid-phase protecting group attached to the 3' position from an oligonucleotide protected with a pseudo solid-phase protecting group having an oxalate ester structure.
Claims
1. A pseudo solid-phase protecting group for use in the preparation of oligonucleotides or oligoamidites, comprising A pseudo solid-phase protecting group represented by the general formula (1), which has an oxalic acid structure at the molecular end that binds to the 3'-hydroxyl group of a nucleoside or oligonucleotide. MO-(O=)CC(=O)-W-X-Y-Z (1) (In general formula (1), -OM represents a linking group that bonds to the 3'-position hydroxyl group of a nucleoside or oligonucleotide; M represents a hydrogen atom (H) or an alkali metal atom; W represents an oxygen atom (O), a sulfur atom (S) or NR (N represents a nitrogen atom, and R represents H or an alkyl group having 1 to 6 carbon atoms); X represents a single bond, an alkylene group having 1 to 12 carbon atoms (which may have an ether bond (-O-)), an arylene group (which may be substituted with an alkylene group having 1 to 3 carbon atoms) or a divalent heterocyclic group; Y represents a single bond, an ether bond, -OCO-, -NRCO- (R is the same as above), -CO- or -SCO-; and Z represents an alkoxyphenyl group or an alkoxyalkyl group having an alkoxy group having 10 to 30 carbon atoms.)
2. A protected nucleoside or oligonucleotide having a 3'-hydroxy group protected by binding a pseudo solid-phase protecting group, A protected nucleoside or oligonucleotide, wherein the pseudo solid-phase protecting group is the pseudo solid-phase protecting group according to claim 1.
3. A method for producing an oligoamidite precursor in which the pseudo solid-phase protecting group is selectively deprotected from the protected oligonucleotide according to claim 2, comprising the steps of: A method for producing an oligoamidite precursor, comprising a selective deprotection step of selectively removing the pseudo solid-phase protecting group from the protected oligonucleotide by mixing the protected oligonucleotide with a nucleophile and a base.
4. The method for producing an oligoamidite precursor according to claim 3, wherein the nucleophile comprises at least one selected from the group consisting of 2-cyanoethanol, 2-bromoethanol, 2,2,2-trifluoroethanol, methanol, ethylene glycol, 1,10-decanedithiol, 2-anilinoethanol, 2-aminobenzyl alcohol, and 2-aminophenol.
5. The method for producing an oligoamidite precursor according to claim 3 or 4, wherein the base comprises at least one selected from the group consisting of triethylamine, N-methylmorpholine, N-methylimidazole, 4-dimethylaminopyridine, 4-pyrrolidinopyridine, pyridine and dipotassium hydrogen phosphate.
6. A method for producing an oligoamidite precursor in which the pseudo solid-phase protecting group is selectively deprotected from the protected oligonucleotide according to claim 2, comprising the steps of: A method for producing an oligoamidite precursor, comprising a selective deprotection step of selectively removing the pseudo solid-phase protecting group from the protected oligonucleotide by mixing the protected oligonucleotide with an aliphatic amino alcohol.
7. The method for producing an oligoamidite precursor according to claim 6, wherein the aliphatic amino alcohol comprises at least one selected from the group consisting of 2-(methylamino)ethanol, 2-[(hydroxymethyl)amino]ethanol, and diethanolamine.
Citation Information
Patent Citations
Hydrophobic group-linked nucleoside, hydrophobic group-linked nucleoside solution and method of synthesizing hydrophobic group-linked oligonucleotide
JP2010275254A
Alkoxyphenyl derivative, nucleoside protector and nucleotide protector, oligonucleotide manufacturing method, and substituent group removal method
JP2020011932A
Method for producing oligonucleotide
WO2012157723A1
Method for producing oligonucleotide
WO2017086397A1
Convergent liquid phase syntheses of oligonucleotides
WO2020227618A2
